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Chapter 1 
INTRODUCTION 
Transplantation of "non-self" tissue is inevita­
bly followed by rejection of the transplanted 
tissue in the unmodified individual unless 
complete genetical identity exists between 
donor and recipient. The first successful 
kidney transplantation in man in 1954 was 
based on genetical identity between donor and 
transplant (Merrill et al., 1956). A successful 
transplantation of kidney bet ween genetically 
non-identical but closely related individuals 
was first achieved in 1959 after total body 
irradiation of the recipient (Hamburger et al., 
1959). After the development of new im­
munosuppressive agents, especially the 6-
mercaptopurine-derivative azathioprine 
(Calne, 1961, Starzl et al., 1963) kidney 
transplantation with organs from living related 
donors became a therapeutic method during the 
middle of the sixties. The success with related 
donors stimulated the application of the 
method also in non-related living and cadaveric 
donors. The great advantages in the use of 
non-related donors were however offset by 
poorer results, apparently dependent upon 
increasing immunological differences between 
donor and recipient. 
The immunological differences between 
individuals of the same species were first 
studied in mice. Several antigen systems of 
varying importance for transplantation, his­
tocompatibility antigen systems, were iden­
tified. One of the systems named the 
H-2 system was found to be of dominating 
importance for graft acceptance and rejection 
(Snell, 1968). Transplantation of skin grafts 
with incompatible H-2-antigens resulted in 
shorter graft survival than transplantation of 
grafts with other incompatible antigens (H-l to 
H-ll). Similar major histocompatibility sys­
tems were found in other species, Ag-B in rat, 
H-l in rabbit, Locus B in chicken etc. 
in man the ABO-system was found to be a 
major histocompatibility system. Transplanta­
tion of a kidney to a recipient with A or B 
antibodies was "safe" only when the kidney 
came from a donor without A or B antigen 
(Starzl et al., 1964). 
Dausset found in 1954 that multiple blood 
transfusions to a patient could give an 
immunological response by formation of 
humoral antibodies directed against t he donor 
leukocytes. Antibodies against leukocytes 
were also demonstrated to be formed after 
pregnancy (van Rood et al., 1958) and after 
experimental skin grafting (Walford et al., 
1962). The antigens, giving rise to leukocyte 
antibodies as an immune response of the host 
after transfusions, pregnancies or transplanta­
tions were found to constitute a complex 
system, first called the Hu-1 system, later the 
HL-A system (Human Leukocyte, locus A) 
(Dausset et al., 1965a. Dausset et al., 1967, 
Bach & Amos, 1967). In many ways this system 
was found to be homologous with the H-2 
system of the mouse (Davies et al., 1968). Like 
the A and B antigens in the ABO-system HL-A 
antigens were found not only on leukocytes but 
also on platelets and cells from various tissues 
in man. HL-A antigens are now thought to be 
present on cells from most of the normal human 
tissues (Berah et al., 1970). The nomenclature, 
the characteristics, the methods of détermina-
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tion and other details of the HL-A system are 
described elsewhere (Dausset, 1971 a and b, 
Kissmeyer-Nielsen & Thorsby, 1970, Thorsby 
et al., 1971b). 
The universally present HL-A antigens may 
by definition give rise to humoral leukocyte 
antibodies in a recipient after transplantation of 
tissue cells with a non-identical HL-A 
specificity. This was found to occur occasion­
ally after blood transfusions as well a s after 
transplantation of skin and other organs 
(Morris et al., 1969b). It was also found that 
these leukocyte antibodies present in a 
recipient after prev ious sensitization impaired 
the survival of the transplanted organ (Fried­
man et al. , 1961, Dausset et al.. 1965 a and b, 
Kissmeyer-Nielsen et al., 1966, Gallinaro et al., 
1967, Mo rris et al., 1968b). Was the possibility 
of form ation of these HL-A-antibodies of any 
importance for the graft survival, and what did 
the immunosuppressive therapy, necessary in 
clinical or gan transplantation, mean? 
Skin graft survival was found to be 
prolonged when HL-A identity existed be­
tween sibling donor and recipient (Ceppellini et 
al., 1969, Amos et al., 1969). An increasing 
degree of HL-A incompatibility was found to 
decrease the survival time of skin grafts from 
living related donors when no immunosuppres­
sion was given (Dausset et al., 1970). Some 
authors found a certain but less convincing 
correlation when unrelated skin donors were 
used (Ceppellini et al., 1969, Batchelor & 
Hacket, 1970). 
Renal graft survival and function was found 
to be superior with HL-A identical sibling 
donors compared to non identical sibling 
donors (Singal et al., 1969, Starzl et al., 1970, 
Hors et al., 1971, Mickey et al., 1971). 
Regarding other living related donors most 
authors have found better results with better 
HL-A compatibility (Rapaport et al., 1967. Lee 
et al., 1967, Terasaki, 1968, Hume et al., 1969, 
Kissmeyer-Nielsen et al.. 1969, van Rood et al., 
1969, Singal et al., 1969, Kissmeyer-Nielsen et 
al., 1970 and 1971, Hamburger et al., 1971, 
Dausset & Hors, 1971, Perkins et al., 1971) 
while some authors found uncertain or no 
correlation (Starzl et al., 1971, Hors et al., 1971, 
Mickey et al., 1971, Halgrimson et al., 1971). 
Concerning transplantations with renal 
grafts from unrelated cadaveric donors many 
authors found better results with HL-A 
identical donors. Some investigators found 
however no difference in the results if ther e 
existed one or more HL-A incompatibilities 
(Morris et al., 1969a, Payne et al., 1971, 
Festenstein et al., 1971a, Hamburger, 1971), 
while others found better results with lower 
incompatibility grades (Batchelor et al., 1971, 
Dausset & Hors, 1971, Festenstein et al., 
1971b, Kissmeyer-Nielsen et al., 1971, Perkins 
et al., 1971). There were also several reports 
from extensive clinical series with n o correla­
tion between histocompatibility grades and 
clinical result after renal t ransplantation with 
either related or unrelated donors (Hume et al., 
1969, Halgrimson et al., 1971, Mickey et al., 
1971, Sheil et al., 1971, Starzl et al., 1971). 
Opinions as to the importance of the HL-A 
system for the results of renal transplantation 
are thus very divergent. Except for the 
deleterious effect of preformed HL-A an­
tibodies against donor lymphocytes there is 
unanimity of opinion only regarding the 
superiority of transplantation with HL-A 
identical siblings. However, this superiority 
has not been proved to be due to the HL-A 
identity; other genetic factors may be responsi­
ble in this very special situation. It may also be 
stated from a review of th e literature that the 
consensus of opinion is that transplantations 
with grafts from HL-A identical unrelated 
donors do better than transplantations with 
grafts from HL-A non-identical unrelated 
donors. Any other conclusion cannot be drawn 
regarding the influence of the HL-A system on 
the results of renal t ransplantation. T heoreti­
cally however, the HL-A system would be 
expected to have greater influence on the 
results of kidney t ransplantations, particularly 
since the transplantation antigens in other 
species have been found to be of profound 
influence for the outcome of organ transplanta-
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tion within these species. The lack of 
correlation between the results of clinical organ 
transplantation and the tissue compatibility 
within the HL-A system may be due to 
imperfect or incorrect 1) selection of patient 
materials, 2) HL-A typing methods, and/or 3) 
interpretation of results. 
Ad 1. Transplantation, especially with nec-
rokidneys, is a very complex therapeu­
tic method and the clinical results are 
influenced by numerous factors. The 
method is used on very different patient 
categories (with different diseases, 
ages, degrees of uremia etc.) and the 
grafts are of very different "quality" 
- and handled in different ways. Even 
more important the treatment, especial­
ly the immunosuppressive therapy, 
varies considerably. One of the great 
difficulties is to obtain a patient material 
large enough but yet reasonably uniform 
and uniformly treated to be able to study 
just one variable factor, the HL-A 
compatibility. In many published re­
ports the results from several transplan­
tation centres have been pooled to 
increase the number of patients in the 
series. This has had the disadvantage of 
increasing the heterogeneity of the 
patient material and patient treatment. It 
has also increased the difficulties in 
evaluating uniformly the transplantation 
results obtained and assessed in differ­
ent transplantation centres. The efforts 
spent in obtaining large patient series 
have thus led to such an increasing 
heterogeneity of patient material, pa­
tient treatment and clinical evaluation 
that conclusions regarding the influence 
of the HL-A system no longer c an be 
drawn. 
Ad 2. The accuracy of the HL-A typing 
method has improved during the last few 
years and has also varied from centre to 
centre. This means that variously 
incomplete HL-A typed transplanta­
tions have been compared to and 
grouped with more accurately HL-A 
typed transplantations. To be able to 
evaluate the importance of the HL-A 
system it is necessary to characterize 
the HL-A antigens accurately and to use 
a uniform, standardized method of 
HL-A antigen identification. This de­
mand for accuracy and uniformity of the 
method of HL-A typing has often been 
disregarded. 
Ad 3. The results of clinical transplantations 
are usually expressed in graft survival 
curves. Graft survival time and graft 
loss are easily and objectively deter­
mined but do not depend on one single 
factor. Should all graft losses be 
registered or some excluded as due to 
other factors than those being ex­
amined? In most of the published 
reports some of the graft losses have 
been excluded. The reason for these 
exclusions has been based more on 
opinions than on facts. The interpreta­
tion of the clinical results has therefore 
been too uncritical. 
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Chapter 2 
PURPOSE 
The purpose of this study was to investigate the 
importance of HL-A compatibility and incom­
patibility fo r graft and patient survival during 
the first year after primary necrokidney 
transplantation, great care being taken to avoid 
the above-mentioned three sources of errors. 
The recipients were selected for transplanta­
tion at one centre on equal conditions, 
transplanted and cared for on one ward with 
standardized immunosuppression and other 
treatment. The whole patient material was 
known personally by the author who partici­
pated in the treatment and follow-up of every 
patient in this series. The grafts were preserved 
by a standardized method. The degree of HL-A 
compatibility was determined retrospectively 
according to the actual knowledge of the HL-A 
system. The transplantation results were 
registered without any exclusions. 
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Chapter 3 
MATERIAL 
Preoperative tissue-typing according to the 
H I.-A system was introduced in the Depart­
ment of Surgery I, Sahlgren's Hospital, 
Göteborg in November 1968. During the first 
months the typing technique was so uncertain 
that not even a retrospective evaluation of t he 
typing protocols made a determination of the 
compatibility grade between donor and reci­
pient possible. From February 1969 the typing 
technique was standardized sufficiently to 
allow the degree of HL-A compatibility 
between donor and recipient to be determined 
by retrospective réévaluation of the typing 
protocols according to the actual knowledge of 
the HL-A specificities. Transplantations per­
formed from February 1st 1969 were therefore 
included in this study. After November 5th 
1970 new graft preservation techniques and 
new immunosuppressive regimes were intro­
duced which made critical comparison with 
earlier transplantations impossible. Transplan­
tations performed after November 5th 1970 
were therefore considered unsuitable and were 
not included in this study. During the period 
February 1st 1969 to November 4th 1970 95 
consecutive primary necrokidney transplanta­
tions were performed. 
When evaluating the results of kidney 
transplantation it is of great importance to 
avoid unwarranted exclusions of patients from 
the material. It is also essential to have a 
uniform standardized method of patient 
treatment. This is especially true regarding 
such treatment which might i nterfere with the 
factors under investigation. Since the purpose 
of this study was to evaluate the significance of 
the degree of HL-A compatibility, a factor of 
possible immunologicaL importance, it was 
essential to have a standardized immunosup­
pressive therapy. Some recipients were given 
an immunosuppression different from the 
routine regime. Therefore 17 transplantations 
were excluded from this study ; these were eight 
patients given extra-corporeal irradiation of the 
blood preoperatively and nine patients treated 
postoperatively with antithymocyte or antilym­
phocyte globulin. This therapy was given as a 
trial a nd the patients were chosen exclusively 
dependent on the actual facilities to give 
extra-corporeal irradiation of the blood, 
antithymocyte or antilymphocyte globulin. 
For the same reasons nine transplantations 
were excluded in which the grafts were treated 
with continuous plasma perfusion according to 
Beizer (Beizer & Kountz, 1970). Continuous 
plasma perfusion might affect immunological 
reactions in different ways. Plasma containing 
humoral antibodies can give rise experimental­
ly to hyperacute rejection in the recipient 
(Collste et al., 1970) and clinical experience 
indicates that an immunological interference of 
plasma exists. Continuous perfusion decreases 
the number of so called passenger leukocytes 
and preserves the viability of the graft better 
which might influence the antigenicity of the 
kidney (Stuart et al., 1971 a and b). The 
continuous perfusion method was chosen to 
obtain clinical experience in nine cases in which 
the other kidney from the same donor was also 
used for transplantation after traditional 
preservation; no other selection was made. 
Four grafts were removed at the time of 
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Diagnosis Patients 
No Per cent 
Pyelonephritis 27 42 
Glomerulonephritis 23 35 
Polycystic kidney disease 11 17 
Eclampsia with cortical necrosis 1 
Malignant hypertension 1 5 
Hypernephroma in single kidney 1 
No. of patients 
30 
G lomerulonephritis • 
Pyelonephritis m 
Polycystic kidney disease 
Other diseases 
Tab. I. Primary causes of uremia. 
transplantation because of technical failures 
(thrombosis, bleeding). One kidney was 
hyperacutely rejected and removed at the same 
operation. In this case the obligatory preopera­
tive cross-match had been considered negative 
but reexamination showed a weak positive 
reaction. The hyperacute rejection in this case 
was undoubtedly due to the presence of 
preformed humoral antibodies. These five 
transplantations in which the grafts were 
immediately removed were also excluded. 
This study thus comprised 64 primary 
necrokidney transplantations on 64 patients 
with a uniform treatment of both the grafts and 
the recipients. 
Recipients 
Since the transplantation program started in 
Göteborg in 1965 the aim has been to give every 
patient with terminal uremia the chance of 
transplantation. The indications have therefore 
been liberal and the contraindications few. 
Patients in this series were accepted up to the 
age of 60. Absolute contraindications were 
malignancy (except kidney tumours), diabetes 
requiring treatment with insulin, active tuber­
culosis, severe psychic disorders and severe 
coronary arteriosclerosis. The recipients came 
from all parts of Sweden. Up to the time of 
transplantation they were cared for in their 
home districts or in the regional nephrological 
department. The patients were generally not 
called to Göteborg until the transplantation was 
forthcoming. 
m 
60 Years 
of age 
Fig. 1. Age distribution and cause of uremia of the 
recipients. 
» 
Age, sex, cause and stage of uremia 
All the diagnoses of the primary renal diseases 
of the patients were confirmed histologically 
after biopsy or after nephrectomy. In the case 
of a non-specific history or non-specific 
pathology a reexamination of the histological 
sections was made and the diagnosis settled 
after thorough discussion. The cause of uremia 
was chronic pyelonephritis in 27 patients 
(42%), chronic glomerulonephritis in 23 
patients (36%) and polycystic kidney disease in 
11 patients (17%). Three patients with uremia 
caused by eclampsia with cortical necrosis, 
malignant hypertension with nephrosclerosis 
and hypernephroma in a single kidney were 
also transplanted (Table I). 
The age range of the recipients was 22 to 59 
years (Fig. 1). Twenty patients (31%) were 
younger than 40 years. 45 patients (70%) were 
males with a mean age of 47 years, 19 were 
females with a mean age of 41 years. 
Though heterogeneous, the pyelonephritic 
11 
No. of patients 
15-. 
Male i I 
Female M No. of patients 
15-
10 
Male I I 
Female m 
m 
60 Years 
of age 
Fig. 2. Age and sex distribution of patients with 
pyelonephritis. 
group was discussed as a unit. The diagnosis 
pyelonephritis was used because of interna­
tional practice although a more adequate 
designation would have been interstitial 
nephritis as the diagnosis pyelonephritis 
included patients with obstructive features, 
congenital abnormalities and drug abuse. 
About half of the patients admitted abuse of 
phenacetin-containing drugs. The highest 
frequency of the disease was in females in the 
age group 30-50 years, while in males the 
incidence increased with increasing age (Fig. 
2). 
The 23 patients with glomerulonephritis 
20 30 40 50 60 Years 
of age 
Fig. 3. Age and sex distribution of patients with 
glomerulonephritis. 
were also discussed as one group. Various 
kinds of glomerulonephritis, possible im­
munological activity, duration or progress 
tempo of the disease etc, were not considered. 
There were predominantly males in this group 
(Fig. 3). 
The eleven patients with polycystic kidney 
disease were transplanted at the age of about 
50. 
The patients in this series did not differ from 
the total material of primary necrokidney 
transplantations during the same period with 
regard to age, sex or cause of uremia (Table II 
and III). 
No Sex dis 
Male 
Per cent 
tr ibution 
Female 
Per cent 
Ma 
Mean 
Age dis 
e 
Range 
tribut ion 
Fen-
Mean 
îale 
Range 
All primary necrokidney 
recipients 
95 67 33 46 22-59 39 19-55 
Investigated material 64 70 30 47 22-59 41 24-54 
Tab. II. Age and sex distribution in the series of patients investigated and in the series of all 95 patients. 
No Pyelonephritis 
Per cent 
Glomerulonephritis 
Per cent 
Polycystic kidney disease 
Per cent 
Other diseases 
Per cent 
All primary necrokidney 
transplantations 
95 39 42 14 5 
Investigated material 64 42 36 17 5 
Tab. III. Distribution of primary renal diseases in the series of patients investigated and in the series of all 95 patients. 
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Different kidney diseases lead to terminal 
uremia at various rates. To be able to estimate 
the rate of progress of e ach patient the aim of 
our department was to be informed about 
patients with incipient uremia as early as 
possible. Some patients in this study therefore 
were waiting for the transplantation for shorter 
or longer time in a fairly good condition. Other 
patients had a rapid progress into uremia or did 
not come for examination until they had 
reached a final uremic state. The facilities for 
hemodialysing during the actual time also 
varied very much from place to place and from 
time to lime. Thus the degree of uremia in the 
recipients, their general condition and the 
frequency of uremic complications varied 
considerably. In this study the duration of 
preoperative dialysis was accounted for, while 
such uncertain factors as mentioned above 
were not considered. In this material 12 
patients (19%) were transplanted in apredialy-
tic phase, 16 patients (25%) after dialysis up to 3 
months, 29 patients (45%) after dialysis for 
3-12 months and 7 patients after more than 12 
months of dialysis. T he average waiting time 
for transplantation was 6 months with wide 
variations. 
Nephrectomy of recipient kidneys 
The importance of removal of the patients' own 
kidneys prior to transplantation is disputed and 
doubtful. Both renal infections and renal 
hypertension might j eopardize the transplanta­
tion results. Hume and others hold the opinion 
that the risk of re current glomerulonephritis in 
the graft is greater if the patients' own kidneys 
are left in place (Hume et al., 1970). Because of 
these possible disadvantages of the patients' 
own kidneys being left in place our indications 
for nephrectomy before transplantation during 
1969 and 1970 were: 
1. Rapidly progressing glomerulonephritis. 
2. Hypertension in patients on hemodialysis. 
3. Recurrent urinary infections in pa tients on 
hemodialysis. 
4. Urinary output of less than 300 ml/day in 
patients on hemodialysis. 
As many patients were treated at other 
hospitals before the transplantation these rules 
were not followed regularly. 
Altogether 15 patients were nephrectomized 
prior to transplantation (Table IV). 
Nephrectomy at the time of transplantation 
(always on the ipsilateral side) was performed 
in five cases with single kidneys or with urinary 
infections. 44 patients had their own kidneys 
left at the time of transplantation; 12 of them 
were nephrectomized within two months after 
the transplantation nine of them within one 
year. The general condition of the patient, the 
degree of hypertension and frequency of 
urinary infections determined the most suitable 
time for nephrectomy. It is obvious that patient 
selection existed with regard to nephrectomy 
before transplantation as well as after 
transplantation. There was no mortality in 
connection with these nephrectomies. 
Donors 
Patients dying in hospitals or brought in to 
hospitals immediately after death were used as 
donors of the grafts in this series. Excluded 
from donation were persons over 70 years of 
No. Own kidneys removed prior 
to transplantation 
Own kidneys removed 
at transplantation 
Own kidneys left 
at transplantation 
Pyelonephritis 27 3 4 20 
Glomerulonephritis 23 10 1 12 
Total investigated 
material 
64 15 5 44 
Tab. IV. Time for nephrectomy of own kidneys (last kidney) in investigated series. 
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age, persons with known or noted kidney 
disease, hypertension or malignancy except for 
tumours in the central nervous system. Only in 
five cases was donor nephrectomy performed 
while the donor was on artificial respiration. 
Cardiac arrest was awaited in the remaining 
cases. Males dominated as donors, 45 (70%) 
were males (Fig. 4). Trauma with or without 
head injury was the cause of death in 33 cases 
(52%), subarachnoid hemorrhage in 17 cases 
(27%) (Table V). One third of the donor kidneys 
came from smaller neighbour hospitals, one 
third from other transplantation centres in 
Scandinavia and one third from our own 
hospital. To preserve organ viability bloodless 
hypothermia was induced immediately after 
the donor nephrectomy. The preservation 
technique used was the method described by 
Brunius et al (1968) in all but two kidneys with 
very short warm ischemia times which were 
perfused with "Collins' solution" (Collins et 
al., 1969). 
The premortem period of the donor was 
often protracted with failing circulation, 
asphyxia, disturbances in fluid- and electrolyte 
balance, failing renal function with oliguria or 
anuria, hypothermia etc. Some of these factors 
might have had great significance not only for 
the viability but also for the immunogenicity of 
the kidney. In this study special attention was 
given to the length of the warm ischemia time 
I iMale 
EÖFemale 
No. of donors 
15-
10-
5-
10 20 30 40 50 60 70 Years 
of age 
Fig. 4. Age a nd sex distribution of the donors. 
(i.e. the time from cardiac arrest until the 
kidney was perfused and cooled) (Fig. 5) and 
the cold ischemia time (i.e. the total time from 
the initial perfusion until the reperfusion in the 
recipient) (Fig. 6). Grafts with a warm ischemia 
time of more than 60 minutes were not 
accepted. 19 grafts (30%) had a warm ischemia 
time shorter than 20 minutes. The cold ischemia 
time varied from 160 to 1000 minutes, but most 
of the grafts, 46 (72%) had a cold ischemia time 
of 5-11 hours. 
Diagnosis of the donor No. of kidneys 
used 
Head injury 27 
Subarachnoid hemorrhage 17 
Extensive trauma 6 
Intoxication 5 
Cerebral tumor 4 
Myocardial infarction 3 
Other 2 
Tab. V. Diagnoses of the donors of the grafts. 
No. of grafts 
20-
10-
10 20 30 40 50 60 
Warm ischemia 
time in minutes 
Fig. 5. Duration of warm ischemia. 
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The degree of ischemic damage of the kidney 
was to some extent reflected in the length of the 
postoperative anuric or oliguric period. The 
"day of onset" of renal function was registered 
as the first day with spontaneously decreasing 
serum creatinine. Six grafts (9%) started to 
function on the day of operation, ten (16%) the 
day after while 19 (30%) started two weeks or 
more after the transplantation (Fig. 7). 
No. of grafts 
15-1 
Cold ischemia 
time in hours 
Fig. 6. Duration of cold ischemia. 
No. of grafts 
io-r 
~L T 
25 
JH j 
30 
Days postoperatively 
15 25 
Fig. 7. Day of onset of renal function. 
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Chapter 4 
METHODS 
Clinical method 
Every available necrokidney was offered to 
bloodgroup compatible recipients within the 
Scandiatransplant organization, comprising all 
transplantation centres in Sweden, Norway, 
Denmark and Finland and including also the 
city of Hamburg, with a common registration of 
all recipients. Priority was given to recipients to 
whom an available kidney was HL-A compat­
ible over recipients to whom the graft was 
incompatible in one HL-A antigen. Grafts with 
one proved incompatibility were generally 
accepted independent of the possibility of 
further unknown antigens, except for patients 
in a very good condition and still in a predialytic 
phase of uremia when a compatible graft was 
pursued. No grafts with two or more known 
HL-A incompatibilities were accepted for 
patients in this series and no patients were 
transplanted as a desperate therapeutic 
attempt. 
Every transplantation was preceded by a 
direct cross-match of donor lymphocytes and a 
fresh sample of recipient serum to identify 
preformed humoral HL-A antibodies against 
the donor lymphocytes. The transplantation 
operations were carried out as acute operations 
as soon as graft and recipient were prepared. 
The operative technique, the postoperative 
care as well as the immunosuppressive therapy 
was well standardized in this series of 
transplantations. An experienced transplanta­
tion surgeon was responsible for every 
transplantation. The kidney was placed ex-
traperitoneally with the renal artery anastom­
osed end-to-end to the internal iliac artery and 
the renal vein end-to-side to the external iliac 
vein. End-to-side anastomosis to the external 
iliac artery was used in a few cases. Two or 
more renal arteries were anastomosed if 
necessary. The donor ureter was implanted in 
the bottom of t he bladder. A ureteral catheter 
was used as a splint to assure proper urine 
outflow. The catheter was removed when a 
normal serum creatinine was established or 
after 10-14 days. Splenectomy or thymectomy 
was not performed. 
The patients were treated postoperatively on 
a special ward by a well trained nursing staff. 
The author participated in the care and 
follow-up of every patient in t his series. 
Postoperative dialysis treatment was prefer­
ably given as peritoneal dialysis for the first 4-6 
days to avoid local bleedings. Hemodialysis 
was then resumed if required. 
No prophylactic antibiotics were given but 
manifest infections were treated with approp­
riate antibiotics. 
Prophylaxis against gastric ulcer was given 
with antacidic and vagus blocking drugs. 
Prophylaxis against oral fungal infections 
was given by local applications of methylrosa-
niline, nystatine and sodium bicarbonate. 
Adequate antihypertensive drugs, cardiotropic 
or other necessary drugs were used individually 
on special indications. Diuretics were not used 
routinely. 
As thrombosis prophylaxis and to improve 
the blood flow in the graft early in e ventual 
rejection episodes low molecular weight 
dextran (Rheomacrodex® ), was given routinely 
the first three postoperative days and then 
twice weekly during the hospital stay. 
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Diagnosis of rejection 
When decreasing kidney function or other 
clinical signs of rejection such as fever, 
pulmonary symptoms, enlargement and tender­
ness of the graft etc. led to the suspicion of 
rejection, other prerenal, renal or postrenal 
causes were first dismissed before the 
diagnosis of rejection was made. Rou tinely a 
renal angiography was performed on the 
4th—6th postoperative day. In case of suspected 
rejection another renal angiogram was made to 
exclude other diagnoses and to strengthen the 
diagnosis of rejection (Nilsson et al., 1968). If 
there was any doubt about the diagnosis of 
rejection a needle biopsy was performed. A 
rejection episode was defined as reversible as 
long as graft function was maintained and 
irreversible when graft function failed. Every 
non-functioning graft in this series was 
removed. 
Immunosuppressive therapy 
The immunosuppressive therapy was based on 
prednisolone and azathioprine. 
Prednisolone was given preoperatively in a 
dose of 100 mg and postoperative initially 200 
mg/day.then in a successively decreasing dose 
to about 1 mg/day/kg body weight a fortnight 
after the transplantation. The dose was then 
further reduced to 10-20 mg/day 2-3 months 
after the transplantation. The mean daily dose 
to recipients with remaining grafts was 1.3±0.0 
mg/kg during the first postoperative month and 
the mean maintenance dose one month after the 
transplantation 0.7±0.0 mg/kg. 
Azathioprine was given preoperatively as 
early as possible (usually only some hours 
before operation) in a dose of 100 mg and 
postoperatively in a dose of 3 mg/kg body 
weight/day as long as no side effects were 
registered. Because of side effects, especially 
leukopenia, the azathioprine dose often had to 
be lowered. In fact this intended dose was given 
to only 31 of the 54 recipients with grafts 
remaining for at least one month. The mean 
daily dose during the first postoperative month 
No of patients 
15-
n 
—r 
4.0 
Azathioprine 
mg/kg/day 
Fig. 8. Mean daily azathioprine dose given during the first 
postoperative month. 
for these 31 patients was 2.9±0.1 mg/kg. The 
other 23 patients received a mean daily dose of 
1.7±0.1 mg/kg (Fig. 8). 
No other immunosuppressive therapy was 
given routinely in this series. When an acute 
rejection was diagnosed the prednisolone dose 
was increased for one or two days, actinomycin 
C was added for five days (200 gamma every 
day) and local x-ray irradiation to the graft was 
given in a dose of 150 rad every second day 
three or four times. The azathioprine dose was 
maintained. 
Long-term control 
The postoperative hospitalization time varied 
from three weeks to three months. The patients 
were then controlled at their local hospitals as 
out-patients one to four times a month. 
Thorough follow-up examinations on the 
transplantation ward were made 6 and 12 
months after the operation and included 
estimations of inulin- and PAH-clearance, 
protein ex cretion and renal an giography. 
All removed grafts were examined histo-
pathologicallly an d special care was taken in 
cases where recurrent glomerulonephritis 
could be suspected. 
All patient who died were autopsied. 
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Statistical methods 
The data in this study are presented as graft 
survival curves and patient survival curves. 
The graft and patient survival time was 
calculated for every transplantation and 
expressed as "whole months after the day of 
transplantation" up to 12 months. All kinds of 
patient and graft losses were registered without 
any selection. Patient loss e.g. also meant graft 
loss even if the graft functioned well at the time 
of death of the recipient. The percentage of 
graft and patient survivals was calculated for 
every postoperative month. Averages were 
calculated and expressed as arithmetic means 
with the standard error of the mean. 
Frequency differences between groups were 
calculated according to the ^--method (K. 
Pearson) and using the tables of Fisher's 
Statistical Method for Research (Oliver & 
Boyd, Edinburgh and London, 1936). 
Methods for histocompatibility determination 
Together with A. Lindholm 
Tissue-typing technique 
The blood group antigens within the ABO-
system and the antigens according to the HL-A 
system were considered. The HL-A antigens 
were determined by the lymphocytotoxicity 
microtechnique described by Terasaki & Mc 
Clelland (1964) and modified by Kissmeyer-
Nielsen & Kjerbye (1967). The lymphocyte 
suspensions were prepared in two different 
ways, one with the albumin flotation technique 
(Kissmeyer-Nielsen & Kjerbye, 1967) and 
another with the technique described by 
Böyum (1968) and modified by Thorsby & 
Bratlie (1970). The HL-A antigens of the 
donors were determined with these two 
lymphocyte suspensions separately. The lym-
HL-A antigens Identified by 
antisera no. 
At the time of 
1 St 
2nd 
series 
series 
1, 2, 3, 9,11, 28 
7, 8,12,13, W5, W10, W15 
29 February 1969 
1 St series 1,2, 3, 9,11, 28,10 
2nd series 7, 8,12,13, W5, W10, W15, 
5, 27, W16, W22, 5(AJ), 
W15(AJ), 27(AJ), W22(AJ) 
45 December 1969 
1 St series 1,2, 3,9,11, 28,10, W19 
2nd series 7,8,12,13, W5, W10, W15, 
5, 27, W16, W22,5(AJ), 63 October 1970 
W15(AJ), 27(AJ), W22(AJ), 
14, W18(SL), W21 (SL), 17 
Tab. VI. HL-A antigens identified during the investigation period. 
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phocytotoxic reactions were read by a trained 
serologist. 
During the period of this investigation the 
number of anti-sera used and thereby the 
accuracy of the HL-A antigen identification 
increased. The increasing number of test sera 
was due to a continuous screening and selection 
of sera obtained from women with multiple 
pregnancies, patients receiving multiple blood 
transfusions and from transplanted patients. 
The exchange of test sera within the 
Scandiatransplant organization also implied an 
improvement in the quality of the test sera. The 
lymphocytes from the very first donors and 
recipients in this material were tested against 29 
anti-sera but already during 1969 the number of 
anti-sera increased to 45. These anti-sera 
identified seven antigens of the first series and 
15 of the second series. The number of anti-sera 
increased successively to 63, identifying eight 
antigens in the first series and 19 in the second 
series (Table VI). 
The specificities of som e anti-sera were not 
known at the time of testing; later experience 
has identified them. The protocols from all 
donor and recipient typings were therefore 
reevaluated according to the actual knowledge 
of the anti-sera used and their specificities. The 
HL-A type of every donor and recipient was 
then settled. This retrospective réévaluation 
increased the accuracy and uniformity of the 
determination of the HL-A-antigens. 
Evaluation of compatibility grade 
In 24 of the recipients and 38 of the donors only 
two or three of t he four theoretically possible 
antigens were identified at the time of 
transplantation. This may be due to either the 
occurrence of homozygotism of one or two 
antigens or to the presence of unk nown HL-A 
antigens. The evaluation of the compatibility 
grade in such cases has been under debate. 
Some authors exclude all "non-full-house" 
transplantations because of the possible 
uncertainty in the determined HL-A 
phenotype. The accuracy of a determined 
HL-A phenotype depends however not only on 
the number of identified a ntigens but a lso on 
the antibody titer and specificity of each 
anti-serum used. No exclusions of "non-full-
house" identifications were made in this study. 
To be able to account for the possibility of 
further non-identified HL-A antigens in case of 
"non-full-house" identification, different 
methods have been used earlier. Some have 
prefered to calculate every possible incompati­
bility and use the term "worst possible 
compatibility grade" for the evaluation (Kiss-
meyer-Nielsen et al., 1970). Others have 
calculated the ratio between found and possible 
incompatibilities and used this ratio to 
determine the compatibility grade (Rapaport & 
Dausset, 1970). None of these methods 
consider however the other possible explana­
tion for the non-identification of one or two 
antigens, namely the possibility of homozygot­
ism. Therefore none of these methods was 
accepted for this study. The compatibility 
grade was instead determined in the following 
ways: 
1. Independent of the number of possible 
incompatibilities only the number of proved 
incompatibilities was considered. 
2. a) 
When different reactions against anti-
sera(s) existed with the donors's and the 
recipient's lymphocytes this was regarded as 
a sign of different HL-A combinations even 
if the incompatible antigen was not 
identified. In this way the most probable 
compatibility grade was determined in five 
"non-full-house" transplantations. 
b) 
When no different reactions existed and 
only two or three antigens were identified 
the chance for homozygotism was calculated 
and the risk of further incompatibilities was 
considered. According to known gene-
frequencies of different HL-A antigens 
among a population of 690 unrelated 
individuals, tested in Göteborg, the chance 
for homozygotism was calculated (Sandberg 
& Lindholm) (Table VII). 
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If the gene frequency of one single defined antigen in 
one locus was "a" and the frequency of the sum of the 
unknown antigens in the actual series was "u" the 
chance for homozygotism was 100 per cent. 
Because of the varying number of anti-sera used during 
the investigation period the "0"-gene-frequency 
varied. In every homozygotism calculation the actual 
"0"-gene-frequency at that time was used (i.e. the given 
figures of chances for homozygotism in Table VII were 
not always used). 
First series 
(LA-locus) 
Second series 
(4 locus) 
HL-A antigen Gene-frequency Chance for homozygotism if 
only one antigen is identified 
in the locus 
Per cent 
1 0.1462 90.9 
2 0.3277 95.7 
3 0.2013 93.2 
9 0.0895 86.0 
10 0.0393 72.9 
11 0.0545 78 9 
28 0.0545 78.9 
W19 0.0797 84.5 
"o" 0.0073 
5 0.0356 22.6 
7 0.1687 58.0 
8 0.1236 50.3 
12 0.1259 50.7 
13 0.0166 12.0 
W 5 0.0646 34.6 
W10 0.1129 48.0 
W15 0.1033 45.8 
14 0.0228 15.7 
W22 0.0116 8.7 
27 0.0476 28.0 
W21(SL) 0.0095 7.2 
17 0.0263 17.7 
W18(SL) 0.0207 14.5 
W16 0.0095 7.2 
5 (A J) 0.0065 5.1 
W15(AJ) 0.0060 4,7 
27(AJ) 0.0207 14.5 
W22(AJ) 0.0065 5.1 
"0" 0.0611 
Tab. VII. Frequencies of identified genes among 690 investigated, non-related individuals and chance of homozygotism if 
only one antigen has been defined in t he actual locus. 
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If th e calculated chance for homozygotism 
exceeded 50% no further antigens were 
accounted for, if the chance for homozygot­
ism was less than 50% one more antigen, 
non-identified, was presumed. After this 
calculation the most probable compatibility 
grade was determined. 
According to these calculations the results of 
the transplantations in this study were 
correlated to: 
1) the number of proved incompatibilities, 
2) the number of most probable incompatibli-
ties. 
When no HL-A incompatibility was proved 
or probable, HL-A compatibility was said to 
exist. 
At the time of tran splantation no incompati­
bility was found on 26 occasions, one 
incompatibility on 38 occasions. Réévaluation 
of the typing protocols revealed one further 
transplantation with one proved incompatibili­
ty and two with two incompatibilities. 
When different serological reactions and the 
chances for homozygotism were considered no 
incompatibility most probably existed in 14 
transplantations, one incompatibility in 36 and 
two incompatibilities in 14 transplantations 
(Fig. 9). 
No incompatibility 
Limitations of the method of compatibility 
determination 
HL-A typing technique 
The technique of HL-A identification is an 
accurate method though involving several 
evaluations of the strength of cytotoxic 
reactions with considerations of both the 
viability of the lymphocytes and the various 
strengths and specificities of numerous anti-
sera. Because of the great number of anti-sera 
used for every HL-A identification false 
positive or negative reactions could hardly be 
overlooked without coming to the attention of a 
trained serologist. 
Only two subloci in the HL-A system were 
considered. The possibilities of other loci have 
been discussed but not yet proven and were 
therefore not considered in this study (Thorsby 
et al| 1970). 
Compatibility determination 
The degree of compatibility must be considered 
somewhat uncertain even in "full-house" 
transplantation. The "0"-antigen frequencies 
are now fairly small but further splitting of the 
already known antigens into more "narrow", 
specific antigens can be expected (Thorsby et 
a!., 1971b). T his will always tend towards a 
lowering of the compatibility grade. 
One incompatibility Two incompatibilities 
Proved at 
operation 
Retrospectively 
proved 
Retrospectively 
most probable 
25 
transplantations 
37 
transplantations transplantations 
38 
transplantations 
transplantations 
26 
transplantations 
transplantations 
36 
transplantations 
Fig. 9. Degree of HL-A compatibility at the time of operation, retrospectively proved and retrospectively most probable. 
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The calculations of the most probable 
compatibility grade includes not only the errors 
of all statistical calculations but also the 
following source of error. As some antigens 
more often seem to be bound together than 
others it might have been more proper to use 
the frequencies of haplotypes instead of genes. 
No such data on the haplotype frequencies 
were available at the time of this investigation. 
Subsequent data from other studies (Högman 
et al., 1972) showed no divergence between 
haplotype and gene frequencies of importance 
for the results in this study. 
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Chapter 5 
RESULTS 
Overall results 
Patient survival 
Sixty-three of all 95 patients primarily 
transplanted with a necro-kidney in Göteborg 
during the period February 1st 1969 to 
November 4th 1970 survived for more than one 
year. Of the 64 patients in this study 43 survived 
one year (Fig. 10). The patient survival rate was 
thus 67% in both the groups which indicated 
that there was no selection of the patients for 
this particular study from the point of view of 
patient survival. Among the causes of death 
(Table VIII) infectious complications were 
most common. Not only the five cases of 
septicemia but also the deaths from cerebral 
hemorrhage, local acute hemorrhage and 
Patient survival 
Per cent 
100i 
50-
12 
Months 
hemopericardium (the patient was operated on 
because of an enterococcus endocarditis) were 
regarded as infectious complications. Fourteen 
of the patients who died had functioning grafts 
64 patients — 
95 patients --
Fig. 10. Patient survival in t he series of transplantations 
investigated and in all 95 transplantations. 
Main cause of death Patient sur­
vival time 
Days 
Septicemia 12 
Septicemia 17 
Septicemia 35 
Septicemia 59 
Septicemia 189 
Cerebral hemorrhage 171 
Cerebral hemorrhage 284 
Hemopericardium (after open heart 
surgery) 
130 
Acute bleeding from grafted site 27 
Acute bleeding from grafted site 66 
Pancreatitis . 54 
Pancreatitis 83 
Myocardial infarction 28 
Heart failure 110 
Pulmonary embolism 79 
Acute rejection with multiple 
bleedings 
57 
Uremia 106 
Gastric ulcer with perforation 32 
Suicide 252 
Carcinoma of the rectum 123 
Acute bleeding after retransplanta-
tion, four months after removal of 
first graft 
307 
Tab. VIII. Main c auses of death. 
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Transplanted 
Dead 
Fig. 11. Overall results. 
while the other seven died at various times after 
transplantectomy (Fig. 11). 
Graft survival and function 
One year after the transplantation 42 of the 95 
primary grafts were still functioning. Twenty-
nine of the 64 grafts in this study functioned for 
more than one year (Fig. 12). These data 
indicate that there was no selection of the 
patients or grafts in the investigated material 
from the point of view of graft survival. 
Fourteen grafts were lost because of patient 
death, 21 removed by transplantectomy (Fig. 
11). The cause of transplantectomy was 
irreversible acute rejection in 17 of the 21 cases 
and acute late bleeding from the grafted site in 
four cases. All grafts removed because of 
irreversible rejection showed histological signs 
of acute cellular rejection. Four of 17 patients 
undergoing transplantectomy because of ir­
reversible rejection were dead within 12 
months. At least three of them died for reasons 
which cannot be related to the transplantec­
tomy or the rejection (uremia, carcinoma of the 
rectum and suicide; 92, 119 and 210 days after 
the transplantectomy) which may indicate that 
the transplantectomies were not performed too 
late in the rejection course. 
Four of the 21 patients who underwent 
nephrectomy were retransplanted during the 
observation period. One of them died because 
Graft survival 
Per cent 
100-I, 
iV 
50-
12 
Months 
3 9 6 
64 grafts _____ 
95 g raft s  
Fig. 12. Graft survival in the series of transplantations 
investigated and in all 95 transplantations. 
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of an acute postoperative bleeding seven 
months after the first transplantectomy. Three 
patients were retransplanted 2-5 months after 
the transplantectomy and were still alive at the 
end of the observation period. In this study 
only their first grafts were considered and their 
survival referred to the first graft. 
Twenty-one of the 29 patients with grafts 
surviving for more than 12 months had an 
unchanged or improved renal function during 
the observation period. One of these 21 patients 
who had his own polycystic kidneys left had 
proteinuria, all the others had a protein 
excretion of less than 700 mg/day. 
Three patients had a slightly decreasing renal 
function during the observation time and 
proteinuria which possibly were signs of 
chronic rejection. Five patients had definite 
chronic rejections with decreasing renal 
function and proteinuria. No patient with a 
remaining graft required dialysis treatment. 
The grafts from the eight patients with 
decreasing renal f unction and proteinuria and 
from the 17 patients subjected to transplantec­
tomy due to irreversible rejection were 
thoroughly investigated for signs of recurrent 
glomerulonephritis. Of these 25 patients eight 
had glomerulonephritis as the primary disease 
while 12 had chronic pyelonephritis. This was 
the same ratio as in the total material of this 
study. The clinical course and the his-
topathological findings excluded recurrent 
glomerulonephritis in all but one case in which 
the diagnosis may be regarded as possible. In 
this study this transplantectomy was accepted 
as due to irreversible rejection. 
First 6 months 
postoperatively 
Per cent 
7th -12th month 
postoperatively 
Per cent 
No rejection 55 83 
One or more rejections, 
serum creatinine again 
< 2.0 mg% 
21 0 
One or more rejections, 
serum creatinine 
> 2.1 mg°/0 afterwards 
24 17 
Tab. IX. Frequencies of reversible rejection episodes (29 
transplantations with graft surviving one year). 
Of the 29 grafts functioning for more than 12 
months 16 (55%) had no clinical rejection 
episodes at all dur ing the first 6 postoperative 
months (Table IX). The other 13 had one or 
more acute rejection episodes, six with good 
restitution of the kidney function, seven with 
remaining but impaired function. During the 
second postoperative half-year 24 had no signs 
of rejection and five had rejection episodes 
with definite reduction of the kidney function. 
Graft survival related to donor factors, recipient 
factors and HL-A compatibility 
Donor factors 
Many conditions in the donor are of importance 
for the viability of the kidney and may also be 
of importance for the immunogenicity of the 
graft. The degree of viability per se may have 
an immunological significance. 
It is not known which factors in the 
premortem phase of the donor are most 
important for organ viability, but factors such 
as blood pressure, organ perfusion, body 
temperature and the nature of trauma or 
disease are thought to be of great importance. 
Reliable data on relevant parameters in the 
premortem phase of the donors are however 
often impossible to obtain retrospectively. This 
investigation was therefore concentrated on an 
evaluation of the influence of age and cause of 
death of the donors and of the duration of warm 
and cold ischemia times on the outcome of the 
transplantation. 
The graft survival rate was therefore 
correlated to the age of the donor. Three age 
groups were considered; up to 30 years, 30-50 
years and above 50 years of age (Fig. 13). The 
graft survival rate was found to be higher if the 
donor was older than 50 years. The influence of 
the diagnosis of the donor was also analysed. 
The graft survival rate was not found to be 
correlated to the disease or trauma of the 
donor. 
The graft survival rate was correlated to four 
different lengths of warm ischemia time, 0-20 
25 
50 
Donor age < 30 years (21 grafts) -— 
30-50 (24 ) ------
> SO di — " —> — — (19
Graft survival 
Per cent 
100 
i 
12 
Months 
50-
1 
Q 12 Months  
Warm ischemia time 0-20 rn'ri 
21-30 
31 -40 
41-60 
( 19 grafts ) 
(24 ) 
( 1 4  )  
( 7 ) 
Fig. 13. Graft survival correlated to age of the donor. Fig. 14. Graft survival correlated to duration of the warm 
ischemia. 
minutes, 21-30, 31-40 and 41-60 minutes (Fig. 
14). The graft survival was poor if the warm 
ischemia time exceeded 40 minutes. The 
differences in graft survival rate were small if 
the warm ischemia time was below 40 minutes; 
a somewhat higher graft survival rate was 
found with a warm ischemia time of 31-40 
minutes. 
An influence of the cold ischemia on the 
graft survival rate was found when the survival 
rate was correlated to different duration of cold 
ischemia, less than 6 hours, 6-10 hours and 
more than 10 hours (Fig. 15). The shorter the 
cold ischemia time the better was graft survival 
rate at one year. With a cold ischemia time of 
more than 10 hours the one year survival rate 
was only 35% with the preservation method 
used in this series. 
The ischemic damage of the graft, occurring 
during the pre- and postmortem phase of the 
donor, often gave rise to an oliguric or anuric 
period in the transplant. The duration of such a 
period may to some extent reflect the severity 
of the ischemic damage; however also other 
factors, including immunological ones, may 
influence the duration of such an oligo-anuric 
period. In this series of transplantations an 
early start of function did not result in any 
significant increase of the one year graft 
survival rate compared to a late start of 
Graft survival 
Per cent 
100 
50 
12 
Months 
Cold ischemia time .<360 min 116 grafts ) 361-600 —125 —•— ) 
>601 123 —'— I  
Fig. 15. Graft survival correlated to duration of the cold 
ischemia. 
Graft survival 
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Graft survival 
Per cent 
100 
50. 
Months 
Day of onset within 5 days (28 patients)  
6th-14th day (17 patients) — — 
after 15 days or more (19 patients)  
Fig. 16. Graft survival correlated to day of onset of renal 
function. 
function of the graft (Fig. 16). 
This analysis emphasizes the influence of 
the duration of warm and cold ischemia and of 
the age of the donor for the graft survival. 
Recipient factors 
Among factors in the recipient possibly 
affecting the results of kidney transplantation 
special interest was focused on the recipient's 
age, cause and stage of uremia and the given 
immunosuppressive therapy. The graft sur­
vival rate was correlated to three different 
recipient age groups: up to 40 years, 40-50 
years and above 50 years of age. The age of the 
recipient was found to influence the graft 
survival (Fig. 17). The highest graft survival 
rate one year a fter transplantation was found 
among recipients in the age of 40-50 years, the 
lowest among recipients below the age of 40 
years. 
The original disease of the recipients was 
found to be of significant i mportance for the 
graft survival (Fig. 18). One year after the 
transplantation the graft survival rate for 
recipients with glomerulonephritis was twice as 
high as the rate for recipients with pyelonep­
hritis. The graft survival rate for recipients with 
polycystic kidney disease was somewhat lower 
Graft survival 
Per cent 
100 
50-
3 6 9 12 
Months 
Patients <40 years old (21 patients! — — 
40-50 (26 ) — 
Fig. 17. Graft survival correlated to age of the recipient. 
than for recipients with glomerulonephritis. 
The influence of the duration of preopera­
tive dialysis treatment on graft survival was 
investigated. The graft survival rate was 
calculated for recipients transplanted before 
initiation of dialysis treatment, for recipients 
dialysed for less than three months, 3-12 
months and for recipients dialysed for more 
than one year. A moderate influence of the 
duration of preoperative dialysis on the graft 
Graft survival 
Per cent 
100 
50-
Months 
Pyelonephritis (27 patients) —-— 
Glomerulonephritis (.23 patients) ——— 
Polycystic kidney disease (11 patients)  
Fig. 18. Graft survival correlated to cause of uremia of the 
recipient. 
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Graft survival 
Per cent 
100 -n. 
50 
3 6 9 12 
Months 
Patients transplanted, prior to dialysis (12 patients) — — 
after dialysis <3 months (16 patients)  
> 1 2  — —  (  7  —  . . — ;  
Fig. 19. Graft survival correlated to duration of the 
preoperative dialysis. 
survival was found (Fig. 19). The highest graft 
survival rate was found among recipients 
transplanted in a predialytic phase or after 
dialysis treatment for more than one year. The 
duration of the preoperative dialysis may also 
influence the frequency of preformed HL-A 
antibodies in the recipient provoked by blood 
transfusions. In this series of patients nine had 
developed HL-A antibodies before the trans­
plantation. Two of these nine grafts survived 
one year. 
The influence of recipient nephrectomy was 
also analysed (Fig. 20). A better graft survival 
was found one year after the transplantation in 
the larger group of recipients with their own 
kidneys left at the time of transplantation than 
in the group nephrectomized before the 
transplantation. 
The immunosuppressive therapy was well 
standardized and all rec ipients were given the 
same prednisolone dose (see page 16). 
Depending on the bone marrow depressing 
effect of azathioprine some of the patients 
however received a lower azathioprine dose 
than that intended. This was the case of 23 
patients who tolerated a mean daily dose of 1.7 
Graft survival 
Per cent 
TOO — 
50_ 
6 12 3 9 
Months 
Patients' own kidneys remowed prior to 
transplantation (15 patients) — 
Patients' own kidneys left at transplantation 
(44 patients ) - — 
Fig. 20. Graft survival in transplantations of recipients 
with own kidneys left or removed (last own kidney). 
Graft survival 
Per cent 
100 
50-
Months 
Mean daily dose of azathioprine 1.7 mg/kg 
(23 patients)  
Mean daily dose of azathioprine 2.9 mg/kg 
(31 patients) —1 ~ 
Fig. 21. Graft survival correlated to the size of the 
azathioprine dose given during the first postoperative 
month. 
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Fig. 22. Graft survival correlated to retrospectively proved compatibility grade. 
1 
24 
Months 
mg/kg bodyweight during the first postopera­
tive month, while 3! patients received the 
intended dose, i.e. a mean daily dose of 2.9 
mg/kg. The influence of different immunosup­
pressive therapy on graft survival was analysed 
(Fig. 21). Of the 64 transplantations in this 
series 54 grafts survived for more than one 
month. The graft survival rate of the 31 
recipients tolerating the higher azathioprine 
dose was higher than the graft survival rate for 
recipients who did not tolerate the intended 
azathioprine dose. This difference was most 
evident during the first months but was still 
present one year after the transplantation. 
This analysis emphasizes the influence of 
the recipient's age and cause of uremia, the 
duration of preoperative dialysis treatment as 
well as the influence of recipient nephrectomy 
and the azathioprine dose given on graft 
survival. 
His toco m pa tibility 
The influence of compatibility and incompati­
bility in the HL-A system was analysed 
according to the different degree of compatibil­
ity defined in chapter IV, i.e. considering 
1) proved degree of H L-A incompatibility and 
2) most probable degree of HL-A incompatibili­
ty. The survival rate of grafts with no proved 
incompatibility was found to be significantly 
higher than the survival rate of grafts with one 
proved incompatibility (Fig. 22). The differ­
ences in g raft survival rates increased during 
the first six months and then remained 
unchanged up to two years after the 
transplantation. 
The survival rate of grafts with no probable 
incompatibility was even higher (Fig. 23). 
There was however no difference in graft 
survival rate if there existed one or two 
probable incompatibilities. 
These data emphasize that compatibility in 
the HL-A system was important for the graft 
survival. 
As other factors both in the donor and in the 
recipient also were found to be of importance 
for graft survival these factors might be 
responsible for the different survival rates of 
compatible and incompatible grafts. The 
distribution of such factors of the donor and of 
the recipient which favoured graft survival, 
"positive factors", were therefore calculated 
within the groups of compatible-graft-
transplantations and compared to the distribu­
tion of these "positive factors" in the total 
material (Table X). No differences were found 
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No incompatibility C14 grafts) —— 
One incompatibility (36 grafts)  
Two incompatibilities (14 grafts)  
Fig. 23. Graft survival correlated to retrospectively most probable compatibility grade. 
Per cent of 
total mate­
rial 
(64 patients) 
Per cent of patients 
with no proved in­
compatibility 
(25 patients) 
Per cent of patients 
with most probably 
no incompatibility 
(14 patients) 
Age of recipient 40-50 years 41 52 50 
Glomerulonephritis as cause of uremia 36 36 36 
Transplanted predialytic 19 32 50 
Transplanted after dialysis >12 months 11 8 7 
Own kidneys left at transplantation 69 76 86 
Mean daily azathioprine dose 2.9 mg/kg 
(to patients with grafts surviving one 
month ) 
57 44 60 
Age of donor >50 years 30 32 29 
Warm ischemia <40 minutes 89 92 100 
Warm ischemia 31-40 minutes 22 16 14 
Cold ischemia < 600 minutes 64 64 64 
Cold ischemia < 360 minutes 25 32 29 
Tab. X. Frequencies of "positive factors" in all transplantations and in transplantations of grafts with no proved or no 
probable HL-A incompatibility. 
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in the distribution o f ' 'positive factors" with 
one exception. There was a higher frequency of 
patients transplanted in a predialytic phase 
among those with "no incompatibility". This 
was expected since patients accepted for 
transplantation in a predialytic phase were 
more often transplanted only if a kidney with 
good compatibility could be offered. This 
moderate difference could however have had 
only minor importance for the better survival 
rates of compatible grafts. As otherwise no 
significant differences existed in frequencies of 
"positive factors" it was evident that no 
selection was made of the grafts or of the 
patients for transplantation with HL-A compat­
ible kidneys. 
HL-A compatibility was therefore accepted 
as a favourable factor. Which of the "positive 
factors" were then the most important one? To 
investigate this the frequencies of all "positive 
factors" found were compared in two groups of 
transplantations, one with grafts surviving for 
more than 12 months and another with grafts 
surviving for less than 12 months (Table XI). As 
expected higher frequencies of "positive 
factors" were found in the group of 
transplantations with grafts surviving for more 
than 12 months. Also the frequencies of all 
other investigated factors, not previously 
found to be "positive", were calculated, but 
none of these factors was found in a higher 
frequency among grafts surviving more than 12 
months than among grafts surviving less than 
12 months. 
The difference in frequencies of each 
"positive factor" could be taken as a measure 
of the relative importance of just that factor. 
The statistical calculation of t hese differences 
gave significant differences only concerning 
the compatibility factors (pcO.Ol if no 
incompatibility was proved, p<0.001 if no 
incompatibility was probable). The differences 
of f requencies of the other "positive factors" 
were not statistically significant. 
This implies that the most important single 
factor for graft survival was compatibility in 
the HL-A system between donor and recipient. 
Per cent of 29 
patients with 
graft surviving 
> 12 months 
Per cent of 35 
patients with 
graft surviving 
<12 months 
Age of donor >50 years 41 20 
Warm ischemia <40 minutes 97 83 
Cold ischemia <600 minutes 72 57 
Cold ischemia <360 minutes 35 17 
Age of recipient 40-50 years 52 32 
Glomerulonephritis as primary disease 48 26 
Transplanted predialytic 21 17 
Transplanted after dialysis >12 months 14 9 
Own kidneys left at transplantation 80 60 
Daily azathioprine dose 2.9 mg/kg 62 52 
No proved incompatibility 55 26 
No probable incompatibility 41 6 
Tab. XI. Frequencies of "positive factors" in transplantations of grafts surviving and not surviving one year. 
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First 6 months 
postoperatively 
7th~12th months 
postoperative I y 
No rejection 
episode 
Per cent 
Reversible 
rejection(s) 
Per cent 
No rejection 
episode 
Per cent 
Reversible 
rejection(s) 
Per cent 
No proved incompatibility 
(16 patients) 
56 44 88 12 
One proved incompatibility 
(13 patients) 
38 62 77 23 
Tab. XII. Frequencies of reversible rejection episodes correlated to proved compatibility grade (29 transplantations of 
grafts surviving one year). 
First 6 months 
postoperat ively 
7th-12th months 
postoperat ively 
No rejection 
episode 
Per cent 
Reversible 
rejection(s) 
Per cent 
No rejection 
episode 
Per cent 
Reversible 
rejection(s) 
Per cent 
Most probably no incompatibility 
(12 patients) 
67 33 83 17 
Most probably one or two incompatibilities 
(17 patients) 
35 65 82 18 
Tab. XIII. Frequencies of reversible rejection episodes correlated to most probable compatibility grade. 
The great importance for graft survival of 
HL-A compatibility should be expected to be 
reflected in a l ower frequency and/or severity 
of rejection episodes. An analysis was 
therefore made of the frequencies of reversible 
and irreversible rejections in HL-A compatible 
and HL-A incompatible grafts. The frequency 
of reversible rejection episodes was slightly 
lower in the compatible grafts than in the 
incompatible grafts but the groups were small 
(Table XII, Table XIII). 
The frequency of irreversible rejections was 
however the same in grafts with no proved 
incompatibility as in grafts with one proved 
incompatibility (Table XIV). Only t he smaller 
group of grafts with most probably no 
incompatibility had a lower frequency of 
irreversible rejections (Table XV) compared to 
the groups of grafts with most probably one or 
two incompatibilities. 
Irreversible 
No 
rejection 
Per cent 
No proved incompatibility 
(25 patients) 
7 28 
One proved incompatibility 
(37 patients) 
9 24 
Tab. XIV. Transplantectomies due to irreversible rejec­
tions correlated to proved compatibility grade. 
Irreversible 
No 
rejection 
Per cent 
Most probably no incompatibility 
(14 patients) 
2 14 
Most probably one incompatibility 
(36 patients) 
11 31 
Most probably two incompatibilities 
(14 patients) 
4 29 
Tab. XV. Transplantectomies due to irreversible rejec­
tions correlated to most probable compatibility grade. 
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Thus another reason for graft loss must be 
responsible for the different survival rates of 
compatible and incompatible grafts. Other 
reasons for graft loss were arterial bleeding 
(four grafts) and loss of patient with remaining 
graft (14 grafts). The distribution of patients 
who died with functioning grafts was therefore 
further analysed. Only one of the 25 recipients 
transplanted with HL-A compatible grafts died 
with a functioning graft as compared to 13 of 37 
recipients (35%) transplanted with a graft with 
one proved incompatibility (Table XVI). No 
patient transplanted with a most probably 
HL-A compatible graft died with a functioning 
graft while 31% respectively 21%' of patients 
transplanted with grafts with probably one or 
two incompatibilities died with remaining 
functioning grafts (Table XVII). 
Summary: Many factors in the donorand in the 
recipient were important for graft survival. The 
most important single factor for graft survival 
was HL-A compatibility. Incompatibility led to 
a higher rate of graft loss mainly because of a 
higher recipient mortality rate. 
These findings required a further analysis of 
factors influencing the patient survival. 
Patient survival related to donor factors, 
recipient factors and HL-A compatibility 
The importance for patient survival of the same 
factors previously investigated for graft 
survival influence was analysed. 
Donor factors 
The age of the donor was not found to influence 
patient survival at one year (Fig. 24). The 
influence of the cause of death of the donor was 
analysed but different survival rates were not 
found in the different diagnostic groups. 
There was only a small difference in patient 
survival on the basis of the duration of the 
warm ischemia time if this did not exceed 40 
minutes (Fig. 25). The best survival rate was 
obtained among recipients receiving a graft 
with a warm ischemia time of 31-40 minutes. 
The patient survival rate was found to be 
higher when the cold ischemia time did not 
exceed 6 hours (Fig. 26). 
These data emphasize the influence of the 
duration of warm and cold ischemia on patient 
survival. 
Recipient factors 
The age of the recipient was found to be 
important for patient survival. Recipients in the 
ages of 40-50 years had the highest survival rate 
and recipients in the ages below 40 years the 
lowest (Fig. 27). 
Dead with functioning graft 
No Per cent 
Retrospectively no 1 4 ; 
proved incompatibility 
(25 patients) 
Retrospectively one 13 35 
proved incompatibility 
(37 patients) 
Dead with functioning graft 
No Per cent 
Retrospectively most probably 0 0 
no incompatibility 
(14 patients) 
Retrospectively most probably 11 32 
one incompatibility 
(35 patients) 
Retrospectively most probably 3 21 
two incompatibilities 
(14 patients) 
Tab. XVI. Mortality of recipients of grafts with no or one 
proved incompatibility correlated to graft function at death 
(excluded is one patient dead after retransplantation seven 
months after primary transplantation). 
Tab. XVII. Mortality of recipients of grafts with and 
without probable incompatibility correlated to graft 
function at death (excluded is one patient dead after 
retransplantation seven months after primary trans­
plantation). 
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Warm ischemia time 0-20min (19 grafts) 
21-30 (24—- ) 
31-40-»- (14--- ) 
41-60 (7 ) 
Fig. 24. Patient survival correlated to age of the donor. Fig. 25. Patient survival correlated to duration of the warm 
ischemia. 
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Fig. 26. Patient survival correlated to duration of the cold 
ischemia. Fig. 27. Patient survival correlated to age of the recipient. 
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Patient survival 
Per cent 
100 
5» 
Pyelonephritis (27 patients) ——— 
Glomerulonephritis C 23 patients)  
Polycystic kidney disease C11 patients) — 
Fig. 28. Patient survival correlated to cause of uremia of 
the recipient. 
The original disease of the recipient was 
found to be important. Recipients with 
pyelonephritis had a lower survival rate than 
recipients with glomerulonephritis or 
polycystic kidney disease (Fig. 28). The 
duration of preoperative dialysis treatment was 
not found to have any significant importance 
for patient survival (Fig. 29). 
There was no difference in survival rates 
observed if the recipients were nephrectomized 
before transplantation or not (Fig. 30). 
As described earlier, the immunosuppres­
sive therapy was well standardized. Some 
recipients however did not tolerate the 
intended azathioprine dose so that they 
therefore received a lower dose. The lower 
azathioprine dose was given to 23 of the 54 
recipients with grafts functioning for more than 
one month; the mean daily dose during the first 
postoperative month was 1.7 mg/kg body-
weight. The other 31 received a mean daily dose 
of 2.9 mg/kg. The patient survival rate was 
found to be higher for recipients receiving the 
lower dose (Fig. 31). 
Patient surviva 
Per cent 
50-
'  ' r—-——-—i 1 
3 6 9 12 Months 
Patients transplanted prior to dialysis (12 patients) 
after dialysis <3 months (16 patients)  
3-12 (29 ) 
> 12 —— ( 7 —— ) 
Fig. 29. Patient survival correlated to duration of the 
preoperative dialysis. 
This analysis emphasizes the influence of 
the recipient's age, cause of uremia and of the 
given azathioprine dose on patient survival. 
Histocompatibility 
The patient survival rate was found to be 88% at 
one year when the patient was transplanted 
with a kidney with no proved HL-A 
incompatibility compared to only 51% if o ne 
incompatibility was proved (Fig. 32). 
When the most probable compatibility grade 
was considered no mortality was found if th e 
patients were transplanted with HL-A compati­
ble grafts (Fig. 33). The mortality rate was 39% 
if one incompatibility was probable and 57% if 
two incompatibilities were probable. 
This significant difference in patient survival 
rate might be explained by other "positive 
factors" if th ey were present more frequently 
in the groups with no incompatibility. The 
frequencies of these "positive factors" were 
therefore analysed in the two groups of 
transplantations with proved or probable HL-A 
compatible grafts and compared to the 
frequencies of "positive factors" in the total 
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Fig. 30. Patient survival in transplantations of recipients Fig. 31. Patient survival correlated to the size of the 
with own kidneys left or removed (last own kidney). azathioprine dose given during the first postoperative 
month. 
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No proved incompatibility C25 patients) 
One proved incompatibility (3.7 patients) 
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Fig. 32. Patient survival correlated to retrospectively 
proved compatibility grade. 
Fig. 33. Patient survival correlated to retrospectively most 
probable compatibility grade. 
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Per cent of all 
64 transplan­
tations 
Per cent of 25 trans­
plantations with no 
proved incompatibility 
Per cent of 14 transplan­
tations with most probab­
ly no incompatibility 
Warm ischemia 31-40 minutes 22 16 14 
Cold ischemia £ 360 minutes 25 32 29 
Age of recipient 40-50 years 41 52 50 
Glomerulonephritis as primary disease 36 36 36 
Mean daily azathioprine dose 1.7 mg/kg 
(to patients with grafts surviving one 
month ) 
43 52 43 
Tab. XVIII. Frequencies of "positive factors" in all transplantations and in transplantations of grafts without proved or 
probable incompatibility. 
material (Table XVIII). No differences were 
found which implied that compatibility in th e 
HL-A system was of significant importance for 
patient survival. 
To investigate which factors were most 
important for patient survival the frequencies 
of "positive factors" were calculated in the 
group of 43 patients who survived for more 
than 12 months and in the group of 20 patients 
who died within one year (Table XIX). The 
differences in frequencies were measures of 
the importance of each factor. The statistical 
calculation of these differences showed 
significant differences in proved compatibility 
rate and in probable compatibility rate 
(p<0.005) while the other differences were not 
statistically significant. 
Summary: Among the factors of importance for 
patient survival after necrokidney transplanta­
tion compatibility in the HL-A system between 
donor and recipient was found to be the most 
important single factor. 
Per cent of 43 
patients surviving 
one year 
Per cent of 
20 dead 
patients 
Warm ischemia 31-40 minutes 23 15 
Cold ischemia £360 minutes 30 15 
Age of recipient 40 - 50 years 49 20 
Glomerulonephritis as primary disease 42 25 
Mean daily azathioprine dose 1.7mg/kg 44 30 
No proved incompatibility 51 10 
Most probably no incompatibility 33 0 
Tab. XIX. Frequencies of "positive factors" in transplantations of patients surviving one year and in transplantations of 
patients who died. 
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Chapter 6 
CONSIDERATIONS OF THE IMPORTANCE 
OF DIFFERENT FACTORS FOR GRAFT 
AND PATIENT SURVIVAL 
When evaluating a clinical method there is 
always a multiplicity of factors which influence 
the end results and have to be considered. This 
is especially true for the method of necrokidney 
transplantation. The great number of important 
factors in the donor and in the recipient and the 
complex immunological reactions and their 
suppression makes it especially difficult to 
evaluate the importance of one specific factor. 
The effect of variations of one factor will easily 
be hidden by the effects of simultaneous 
variations of o ther factors. Although the main 
purpose of this study was to evaluate the 
influence of compatibility in the HL-A system 
between donor and recipient, it was necessary 
first to find and evaluate other factors of 
importance for the clinical outcom e. 
The clinical method of transplantation, 
regarding patient and graft selection, im­
munosuppressive regimen etc. varies at 
different transplantation centres which makes 
a comparison of results between different 
centres impossible. It therefore became 
necessary first to evaluate the importance of 
some relevant factors in the donors and in the 
recipients of this specific transplantation 
series. The parameters studied were chosen on 
the basis of known and expected importance 
for graft and patient survival. The factors 
studied were some of the most important 
according to our own experience and that of 
others, but certainly not all which might 
influence the results of transplantation. 
The material in this study was chosen to 
provide a Uniformely treated patient series. 
Also other factors e.g. graft preservation 
technique were standardized as far as possible. 
Therefore this series of transplantations was 
considered very suitable for a study of the 
effect of various factors on the result of 
transplantation. Several factors were found to 
be of importance for graft and patient survival. 
One way to diminish the multiplicity of relevant 
factors when studying the effect of one or few 
factors was to divide the recipients into 
smaller, less heterogeneous groups. The 
disadvantages of such a method were obvious. 
Too small grou ps of patients would not allow 
for well founded conclusions. Instead of 
performing such selections another method 
was chosen. The influences of various factors 
on the end results, i.e. on the graft and patient 
survival rates were studied on the whole series 
of pati ents. D ifferent quantities or qualities of 
every factor studied were correlated to the 
graft survival rate and to the patient survival 
rate. Independent of t he actual validity of just 
one defined factor the group of patients with 
that factor had a certain survival rate. Some 
factors were found to be "positive factors" for 
survival. A comparison was then made of the 
frequencies of these "positive factors" in two 
different groups of patients, one with graft 
survival (or patient survival) more than 12 
months and another with graft survival (or 
patient survival) less than 12 months. It was 
consistent to find a higher frequency of 
"positive factors" in the group of patients with 
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(graft) survival than in the group of patients not 
surviving or with grafts not surviving. The 
differences in frequencies of these factors were 
measurements of the importance of the 
individual factor. In the following the diferent 
graft factors which were found to influence the 
graft and patient survival will be considered 
first, then the different recipient factors and 
finally the HL-A-compatibility grade. 
Graft factors 
The biological event within a graft before the 
transplantation both in the donor and during the 
extracorporeal handling has been thought to 
have importance mainly for the viability of the 
organ, but may also have importance for the 
immunogenicity of the graft. 
Viability of the graft 
Donor factors 
The earlier history of the donor was often 
unknown or very badly known. The risks of 
lower viability of the kidney due to earlier 
diseases must be considered small though 
possible. A m ore important factor might have 
been the premortem phase of the donor. During 
a protracted premortem phase an insufficient 
perfusion of the kidney exists for shorter or 
longer time. The most ideal donor situation 
when nephrectomy can be performed on a 
donor with maintained artificial respiration and 
circulation was very rare in this material. Some 
donors suffered a sudden death; others had a 
period of maximal premortal stress with release 
of v asoactive substances. Others were heavily 
treated during resuscitation attempts with 
vasoactive and cardiotropic drugs for a shorter 
time before the donor nephrectomy. Others 
were "treated" for days with artificial 
respiration though braindead, awaiting spon­
taneous cardiac arrest, which then often 
occurred at a body temperature of about 28°C 
after an oliguric-anuric period of several days. 
The premortem factors were too complex 
and too badly registered to allow a proper 
evaluation in this series. 
Organs from young donors have been 
regarded as more resistent to ischemic damage 
than organs from old donors. It was therefore 
surprising to find a higher graft survival rate 
when the donor age was above 50 years (Fig. 
13). The reason for this finding might be a more 
critical selection of older donors, a better 
capacity to resist premortally released vasoac­
tive or toxic substances, a decreased im­
munogenicity or an unequal distribution of 
other favourable factors. Whatever may be the 
reason the group of recipients with grafts from 
donors over the age of 50 years had a higher 
graft survival rate than the group of recipients 
with grafts from younger donors. The patient 
survival rate was however not influenced by 
the age of the donor (Fig. 24). 
Preservation 
The duration of ischemia periods and the 
perfusion technique are known to have great 
influence on the kidney viability. The perfusion 
technique used in this material was well 
standardized and with two exceptions the same 
perfusates were used in all grafts. The 
carefulness of the initial perfusion may have 
some importance but only small variations in 
this aspect were expected. 
The viability ought to be better the shorter 
the warm ischemia time. Despite this the graft 
survival rate was not superior if the warm 
ischemia time was less than 20 minutes 
compared to an ischemia time of 21-40 minutes 
(Fig. 14). Except for an unequal distribution of 
recipients in the groups, this could be explained 
by the fact that a careful proper nephrectomy 
technique prolongs the warm ischemia time but 
protects the kidney from traumatic damage. 
One important observation is that very short 
ischemia times were very rare in this material. 
Warm ischemia time exceeding 40 minutes 
resulted in a low graft survival rate. 
A direct relation between the duration of the 
cold ischemia and the rate of graft loss was 
noted (Fig. 15). 
The duration of the warm and cold ischemia 
periods influenced not only the graft survival 
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but also the patient survival. This might be an 
effect of a prolonged decreased graft function 
or an effect of changed immunological 
conditions due to the ischemic damage. One 
consequence of long ischemia times was 
observed which might have influenced the graft 
and patient survival. There was a higher 
frequency of postoperative local infectious 
complications (wound infections and urinary 
infections) in the recipients receiving grafts 
with prolonged ischemia times (Fig. 34, Fig. 
35). 
The length of the warm ischemia and cold 
ischemia times had importance for the duration 
of the postoperative oliguric-anuric period. The 
duration of this period could therefore be taken 
as a measure of the degree of ischemic damage. 
In addition other factors were important for the 
duration of t his period, e.g. rejection episodes 
and postoperative local complications. The 
small variations in gr aft survival according to 
"day of onset" were therefore of minor 
interest. 
Immunogenicity of the graft 
Very little is known about factors influencing 
the immunogenicity of the graft. Earlier 
disease, the age of the donor as well as damage 
to the kidney, pre- or postmortally might be 
important. The perfusion technique may at 
least have importance in that an improper 
perfusion or an improper perfusate leaves 
passenger leukocytes of immunological signifi­
cance (Stuart et al., 197i a and b). The 
immunogenicity of different HL-A antigens 
and HL-A compatibility grade will be discussed 
below. 
Recipient factors 
Various conditions in the recipient had 
importance either of immunological signifi-
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Fig. 34. Postoperative infectious complications correlated to the duration of warm ischemia. 
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cance or for the patient's ability to survive. The 
immunological significance was evident in 
cases in which the graft had to be removed 
because of irreversible rejection. An im­
munological reason could not be excluded in 
the case of transplantectomy due to acute late 
arterial bleeding from the grafted site. More 
debatable were the causes of patient death. 
Some of the deaths could be described as 
"non-immunological" patho-physiological 
courses, e.g. death after acute shock-
provoking bleedings or after myocardial 
infarction. The important fact was however 
that a primary interference with immunological 
events could not be excluded. Even the most 
evident "non-immunologcial" death might 
very well be "immunological", i.e. due to 
unknown consequences of the immunores-
ponse. It was therefore considered exceedingly 
important not to exclude any patient from the 
material and not to have preconceived opinions 
about the causes of death. 
Age, sex, cause and stage of uremia 
There was an early and marked difference in 
graft and patient survival rate in the different 
age groups (Fig. 17, Fig. 27). It was notable that 
younger recipients had the lowest survival rate. 
This might be due to a different character of the 
original d isease in younger patients or due to 
different immunological reactions of these 
patient. Kidney diseases rapidly leading to 
uremia in younger patients might be more 
malignant than slow-progressing diseases in 
older patients, concerning both immunological 
activity and direct life-threat. 
The great differences in graft and patient 
survival of the two main diagnostic groups, 
pyelonephritis and glomerulonephritis was 
remarkable (Fig. 18, Fig. 28). Both of the 
diagnostic groups were heterogeneous but the 
poor results of transplantation of pyelonephri-
tic patients have been noted earlier in our 
series. The difference in survival rate was not 
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infections nfections 
Cold ischemia time <360 min.(16 grafts) HU 
361-600 (25 —) ÜC 
>601 -„-(23—m—) = 
>  7 2 0  - „ - ( 1 0 — • )  
Broncho­
pneumonia 
ii 
Septicemia 
Fig. 35. Postoperative infectious complications correlated to the duration of cold ischemia. 
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Graft survival 
Per cent 
100 
50-
9 12 3 6 
Months 
Male recipient (14J " 
Female i i ( 13 ) - — — — 
Fig. 36. Graft survival correlated to sex of the recipients 
with pyelonephritis. 
due to the difference in sex distribution 
between patients with glomeruloneprhitis and 
pyelonephritis. The graft survival and patient 
survival was namely the same for males and 
females in the pyelonephritis group (Fig. 36, 
Fig. 37). 
One possible explanation for this difference 
in survival rates was a difference in im­
munological events in recipients with 
glomerulonephritis and recipients with 
pyelonephritis. Pyelonephritis with urinary 
infections does affect the immunological 
defence mechanism of the patient. Antibodies 
developed against bacterial a ntigens might be 
able to "cross-react" against other antigens 
e.g. H1.-A antigens or kidney antigens (Holm et 
al., 1972). Another possibility might be that 
patients with perpetual infections become 
immunological "strong" with a highly a ctive 
immunoresponse mechanism. 
Patients with polycystic kidney disease 
ought to be ideal transplantation candidates 
with slow-progressing uremia and ideal age. 
The results were however not better than for 
the glomerulonephritic patients. As urinary 
tract infections were fairly common in 
polycystic kidneys a certain resemblance to the 
Patient survival 
Per cent 
100 
50-
3 9 6 12 
Months 
Male recipient (14) 
Female .. (13) •• 
Fig. 37. Patient survival correlated to sex of the recipients 
with pyelonephritis. 
Graft survival 
Per cent 
12 
M o n t h s  
40 - 50 years of age and glomerulonephritis 
(11 patients) —— 
< 40 years of age and pyelonephritis 
(9 patients)  
Fig. 38. Graft survival correlated to age and cause of 
uremia. 
course of pyelonephritic patients might explain 
the results. 
A finding supporting these theories of 
different immunological response capacity 
according to age and original disease of the 
recipient was the low graft survival rate of 
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younger recipients with pyelonephritis com­
pared to the high graft survival rate of older 
recipients with glomerulonephritis (Fig. 38). 
The duration of preoperative hemodialysis 
treatment had little inf luence on graft survival 
and no influence on patient survival (Fig. 19, 
Fig. 29). The higher graft survival rate in 
predialytic transplanted patients might be due 
to less risk for sensitization against HL-A or 
other antigens by less number of g iven blood 
transfusions. The higher graft survival rate in 
recipients dialysed for a long time might also 
have an immunological explanation. Patients 
on hemodialysis for a longer time receive more 
blood transfusions. Some of them then develop 
HL-A antibodies and their chances of obtaining 
a graft decreases ; the preoperative cross-match 
with their serum and the potential donor 
lymphocytes will often be positive. Patients 
who do not develop HL-A antibodies despite 
multiple blood transfusions have thus a better 
chance of obtaining a kidney for transplanta­
tion. Because of their inability to develop 
HL-A antibodies they have been called "bad 
responsers", immunologically "weak" reci­
pients with greater ability for graft acceptance 
(Opelz et al., 1972). 
The different graft survival rates in patients 
with and in patients without their own kidneys 
remaining at the time of transplantation was 
found to be small and the patient survival was 
not influenced at all (Fig. 20, Fig. 30). The 
observed difference in graft survival could not 
be ascribed to the nephrectomy as this 
operation was performed only for specific 
indications. The graft survival curves may just 
indicate that these indications should be further 
limited. 
Immunological aspects 
An important factor for graft survival is the 
immunological competence of the recipient. 
No. of 
patients 
Mean daily aza­
thioprine dose 
Mg/kg 
No proved incompatibility 21 2.4 
One proved incompatibility 32 2.4 
Most probably no incompatibility 14 2.4 
Most probably one incompatibility 30 2.4 
Most probably two incompatibilities 10 2.2 
Tab. XX. Mean daily azathioprine dose during the first postoperative month correlated to the degree of compatibility. 
No. Recipient dead with Transplantectomy due to 
functioning graft rejection bleeding 
HL-A compatible graft 4 1 3 0 
HL-A incompatible graft- 6 2 1 3 
Tab. XXI. Grafts lost within one month. 
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Age and original disease have already been 
mentioned äs factors which probably influence 
this capacity. The problem of varying 
immunological competence of the recipients 
can also be expressed in another way. The 
fairly well standardized immunosuppressive 
regimen is sufficient for immunologically 
"weak" recipients but not for immunologically 
"strong" patients. Hence it is not only a 
question of immunological strength but a 
question of a counteraction of this power by the 
immunosuppressive therapy. In this series of 
transplantations all the patients received the 
same prednisolone dose. The same mean daily 
dose of azathioprine was given to recipients 
receiving HL-A compatible and HL-A incom­
patible grafts (Table XX). The variations in 
immunosuppressive therapy described earlier 
were dependent entirely on the individual 
bone-marrow depressing effect of azathiop­
rine. As apparent from fig. 21 and fig. 31 a 
higher azathioprine dose resulted in a higher 
graft survival rate but a lower patient survival 
rate. These findings require further analysis. 
Of the 64 grafts in this study 10 were lost 
within one month (Table XXI). The recipients 
of 23 of the remaining 54 grafts were given a 
lower azathioprine dose than that intended, 1.7 
mg/kg/day, the other 31 a dose of 2.9 
mg/kg/day. Ten of those 31 recipients (32%) 
were dead within one year (Table XXII). The 
mean daily dose for those ten patients was 
3.0±0.0 mg/kg and until the beginning of the 
final complications they received an unchanged 
dose. All of them died with functioning grafts 
and all of them were transplanted with proved 
HL-A incompatible grafts. Of the 21 surviving 
recipients receiving the higher azathioprine 
dose three lost their grafts (one of eleven 
compatible, two of ten incompatible) within 
one year (Table XXIII). 
Of the 23 recipients receiving the lower 
azathioprine dose four (17%) died within one 
year (Table XXII). All four were transplanted 
with proved HL-A incompatible grafts but only 
one patient died with a functioning graft; the 
other three died 4-7 months after transplantec-
tomy due to irreversible rejection. Of the 19 
surviving patients receiving the lower azathiop­
rine dose eight lost their grafts (4/10 
compatible, 4/9 incompatible) within one year 
(Table XXIII). These findings indicate that 
there was only a minor difference in survival 
rate of HL-A compatible and incompatible 
grafts provided the recipients received the 
same azathioprine dose and survived (Table 
Mean daily azathioprine dose No. of Recipients dead within one year 
patients Totally With proved incompatible graft With functioning graft 
2.9 mg/kg 3 10 10 10 
1.7 mg/kg 2 4 4 1 
Mean daily azathioprine dose Graft survival >12 months 
Totally Of compatible grafts Of proved incompatible grafts 
2.9 mg/kg 18/21 10/11 8/10 
1.7 mg/kg 11/19 6/10 5/9 
Tab. XXII. Mortality of 54 patients with grafts surviving > 1 month, correlated to azathioprine dose given during the first 
postoperative month. 
Tab. XXIII. Graft survival in 40 patients surviving one year correlated to azathioprine dose given during the first 
postoperative month. 
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XXIV, Table XXV). There was however a 
difference in graft survival directly correlated 
to the given azathioprine dose independent of 
HL-A compatibility grade. The recipients 
receiving the higher azathioprine dose had a 
higher mortality than the recipients r eceiving 
the lower dose. The mortality occurred only 
among recipients receiving HL-A incompatible 
grafts. 
Thus a high azathioprine dose was favoura­
ble for graft survival independent of compati­
bility grade but unfavourable for survival of 
recipients with HL-A incompatible grafts. 
Histocom pa tibili t y 
The most important single factor for graft 
survival in this series was found to be 
compatibility in the HL-A system. Compatibili­
ty did not imply absence of rejections; the 
frequency of transplantectomies due to irrever­
sible rejections was the same as for incompati­
ble grafts. The marked difference in graft 
survival rate was found to be related to the 
patient survival rate. Patients transplanted with 
incompatible grafts had a higher mortality rate 
and they often died with functioning grafts. 
Compatibility was also found to be the most 
important single factor for patient survival. 
Of the 25 recipients transplanted with HL-A 
compatible grafts three died within one year, 
one of them with a functioning graft, two after 
transplantectomy. Of the 39 recipients t rans-
Mean azathio­
prine dose 
Mg/kg/day 
No. of 
patients 
One year patient 
survival rate 
Per cent 
One year graft survival 
rate of surviving patients 
Per cent 
No proved 1.7 10 100 60 
incompatibility 
(21 transplantations) 2.9 11 100 91 
One proved 
incompatibil ity 
(33 transplantations) 
1.7 
2.9 
H* 
20 
82 
50 
55 
80 
After exclusion of two patients dead >7 months after transplantectomy (suicide, bleeding after retransplanta-
tion) 
Tab. XXIV. Graft and patient survival correlated to proved compatibility grade and given azathioprine dose. 
Mean azathio­
prine dose 
Mg/kg/day 
No, of 
patients 
One year patient 
survival rate 
Per cent 
One year graft survival 
rate of surviving patients 
Per cent 
Most probably no 1.7 5 100 80 
incompatibility 
89 ! 14 transplantations) 2.9 9 100 
Most probably one 1.7 12u 83 40 
incompatibility 
59 80 (30 transplantations) 2.9 17 
Most probably two 1.7 4» 100 75 
incompatibilities 
100 <10 transplantations) 2.9 5 40 
1) After exclusion of one patient dead >7 months after transplantectomy (bleeding after retransplantation) 
2 )  After exclusion of one patient dead >7 months after transplantectomy (suicide) 
Tab. XXV. Graft and patient survival correlated to most probable compatibility grade and given azathioprine dose. 
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planted with proved HL-A incompatible grafts 
18 died within one year, 13 with functioning 
primary grafts. These findings require a further 
analysis of the patient deaths, especially of 
deaths occurring despite functioning graft. 
The causes of d eath were mainly infectious 
complications, thromboembolic or bleeding 
complications (Table XXVI). The incompati­
bility however did not lead to more frequent 
postoperative local complications (Fig. 39) as 
distinquished from prolonged ischemia times 
(Fig. 34, Fig. 35). 
Most patients died later than one month after 
the transplantation. Four of them had clinical 
and histo-pathological signs of rejection during 
the final course (Table XXVI). It might be 
possible that transplantectomy could have 
saved their lives. None of these rejections was 
of the clinically irreversible type and they were 
probably provoked by an intentionally reduced 
immunosuppressive therapy. Thus, with stan­
dardized immunosuppressive therapy incom­
patibility in the HL-A system often led to death 
of the recipient despite functioning graft. The 
death occurred fairly late and was caused by 
infectious, thrombo-embolic or bleeding com­
plications. 
Main cause of death Patient sur­
vival time 
Days 
Signs of 
rejection 
at death 
Septicemia 12 -
Septicemia 17 -
Septicemia 35 ( + ) 
Septicemia 59 -
Septicemia 189 -
Cerebral hemorrhage 171 + 
Cerebral hemorrhage 284 -
Hemopericardium (after-
open heart surgery) 
130 
Pancreatitis 54 -
Pancreatitis 83 + 
Myocardial infarction 28 -
Heart failure 110 -
Pulmonary embolism 79 -
Acute rejection with 
multiple bleedings 
57 + 
Tab. XXVI. Main cause of death of 14 patients who died 
with functioning grafts. 
Per cent of trans­
planted patients 
TOO 
50 
No proved incompati­
bility C25 patients) 
One proved incompati­
bility C 37 patients') 
• 
r* r 
Local 
infections 
Urinary 
infections 
Septicemia 
Fig. 39. Postoperative infectious complications correlated to proved incompatibility grade. 
Broncho­
pneumonia 
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Per cent Per cent of patients with one 
of total proved incompatibility 
material and graft survi­ and graft survi­
val >12 months val <12 months 
(13 patients) (24 patients) 
Age of recipient 40 - 50 years 41 46 29 
Glomerulonephritis as cause of uremia 36 54 33 
Transplanted predialytic 19 0 25 
Transplanted after dialysis >12 months 11 23 12 
Own kidneys left at transplantation 69 62 67 
Mean daily azathioprine dose 2.9 mg/kg 57 62 54 
Age of donor > 50 years 30 46 25 
Warm ischemia <40 minutes 89 93 83 
Warm ischemia 31 - 40 minutes 22 38 12 
Cold ischemia < 600 minutes 64 77 63 
Cold ischemia < 360 minutes 25 31 25 
Tab. XXVII. Frequencies of "positive factors" in transplantations of proved incompatible grafts, surviving or not 
surviving one year. 
Loss of compatible kidneys 
The graft survival was found to be superior 
after transplantation with HL-A compatible 
grafts (Fig. 22, Fig. 23). During the first 12 
months hov/ever, nine of the 25 compatible 
grafts were lost. One patient died with a 
functioning graft due to septicemia 17 days 
after the transplantation. Seven grafts were 
removed because of irreversible rejection and 
one graft because of acute bleeding from the 
grafted site. 
Of the 14 grafts with most probably no 
incompatibility two were removed because of 
irreversible rejection. 
Thus HL-A compatibility between donor 
and recipient d id not hinder irreversible graft 
rejection. 
Long-term functioning incompatible kidneys 
The graft survival r ate was found to be lower 
after transplantation with HL-A incompatible 
grafts (Fig. 22, Fig. 23). One year after the 
transplantation however 13 of the 37 grafts with 
one proved incompatibility and 12 of the 36 
grafts with most p robably one incompatibility 
still w ere functioning. 
One explanation for this might be an 
accumulation of "positive factors" among the 
functioning kidneys. Therefore the frequencies 
of earlier stated "positive factors" for graft 
survival were analysed in the group of 
transplantation with graft survival more than 12 
months and compared to the same frequencies 
in transplantations with graft survival less than 
12 months (Table XXVII, Table XXVIII). Most 
of the "positive factors" were found to be 
more frequent in transplantations with grafts 
surviving for more than 12 months, i .e. other 
factors favouring graft survival might have 
counteracted the disadvantages of HL-A 
incompatibility in the group of transplantations 
with graft surviving for more than 12 months. 
Another possible explanation for the dif­
ferent course of transplantations with incom­
patible grafts might be a difference in severity 
of the proved HL-A incompatibility. Various 
HL-A antigens might be of various 
"strengths", "weaker" antigens more easy to 
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Per cent Per cent of patients with most 
of total probable one ncompatibility 
material and graft survi­ and graft survi­
val >12 months val <12 months 
(12 patients) (24 patients) 
Age of recipient 40 - 50 years 41 67 17 
Glomerulonephritis as cause of uremia 36 67 33 
Transplanted predialytic 19 0 25 
Transplanted after dialysis >12 months 11 25 8 
Own kidneys left at transplantation 69 67 62 
Mean daily azathioprine dose 2.9 mg/kg 57 67 54 
Age of donor > 50 years 30 50 17 
Warm ischemia < 40 minutes 89 92 83 
Warm ischemia 31 - 40 minutes 22 25 17 
Cold ischemia S 600 minutes 64 75 54 
Cold ischemia < 360 minutes 25 50 12 
Tab. XXVIII. Frequencies of "positive factors" in transplantations of most probably incompatible grafts, surviving or 
not surviving one year. 
transplant against (Hildeman, 1970). The 
incompatible HL-A antigen may also some­
times have a more or less pronounced 
"resemblance" to one of the recipients own 
antigens; such a relationship between certain 
HL-A antigens have been defined by the 
capacity of specific HL-A antibodies to react 
also against other specific HL-A antigens 
(Dausset & Hors, 1971, Kissmeyer-Nielsen et 
al.I 1971, Thorsby et al., 1971b). An 
incompatibility with crossreacting antigens 
might imply a weaker antigen possibly inducing 
a weaker immune response in the recipient. To 
investigate if there were any such difference in 
"strength" of the different HL-A specificities 
in this series of transplantations performed 
against one specific proved HL-A incompati­
bility, the proved HL-A incompatibilities 
leading to graft loss within 12 months were 
compared to the proved HL-A incom­
patibilities leading to graft survival (Table 
XXIX). In addition the possibility of cros­
sreacting antigens according to Thorsby were 
considered. It was found that very often the 
same specific HL-A antigen led to either graft 
Incompatible HL-A antigen 
of graft surviving of graft surviving 
> 12 months < 12 months 
2*\ 2 
g*) 
10 
11 11*!ll1ll1 
28*) 
W19 W19 
•J *) J*) J*) J*) J 
12,12 12,12 
wioi wio*) 
W15*Î W15 
W5,W5 W5 
27<AJ)*>, 27(AJ) 
5(AJ)*> 
27») 27 
5 
P, P. O, o 
13 
W22*> 
'Cross reactivity with recipient antigen possible 
Tab. XXIX. Incompatible HL-A antigens of 13 grafts 
surviving one year and grafts not surviving one year. 
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loss or graft survival. There was a slight 
difference in graft survival if the incompatibili­
ty belonged to the first series (5/11 survived) or 
to the second series (8/26 survived). Possible 
cross-reactivity did not seem to improve the 
results. 
One more aspect on the functioning 
incompatible grafts should be emphasized. As 
pointed out earlier the graft survival rate was 
higher if the recipient received a higher 
azathioprine dose independent of the compati­
bility grade. On the other hand the mortality 
rate also rose. Two conditions might then 
explain why HL-A incompatible grafts re­
mained functioning: 
1. The recipient received a lower azathioprine 
dose (and thus survived) which however for 
this special recipient meant a sufficient 
immunosuppression. The recipient might 
have been a "weak" responder or even 
more probable, the recipient was given a 
kidney with better compatibility in other 
relevant antigen systems outside the HL-A 
system. 
2. The recipient was given a higher azathiop­
rine dose and thus a more sufficient 
immunosuppression but survived despite 
the high azathioprine dose. The ideal 
condition with sufficient but not deleterious 
immunosuppression happened to occur. 
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Chapter 7 
GENERAL DISCUSSION 
The purpose of this study was to investigate the 
clinical importance of HL-A compatibility and 
incompatibility for the outcome of primary 
necrokidney transplantation. Two principles 
were considered to be of special importance for 
this evaluation, namely the demand for a 
uniform treatment of the grafts and of the 
recipients and the demand for avoidance of any 
selection of the patients. 
Some defined factors of importance for graft 
survival were evaluated separately. Several 
factors were found to be of gr eat importance 
but the most important single fac tor for graft 
survival was HL-A compatibility between 
donor and recipient. The graft survival rate was 
significantly higher when no HL-A incompati­
bility was proved and the graft survival rate was 
even higher when no HL-A incompatibility 
most probably existed, according to calculated 
chances for homozygotism of single antigens. 
The superior survival rate of compatible grafts 
was not due to a significantly lesser number 
and/or severity of rejection episodes but to a 
superior patient survival rate. The mortality 
was significantly higher if HL-A incompatibili­
ty existed. Most of these patients who died had 
functioning grafts. In fact loss of the recipient 
was the most common cause of loss of 
incompatible grafts. The causes of patient 
death were mainly infectious complications or 
conditions related to thrombo-embolic or 
bleeding complications, usually appearing 
fairly late after the transplantation. Among the 
investigated factors found to be of importance 
for patient survival, HL-A compatibility was 
the most important single factor. Again the 
significantly better patierrLsurvival with HL-A 
compatible grafts became even more evident 
when HL-A compatibility most probably 
existed. 
Thus the HL-A compatibility between donor 
and recipient was found to be more important 
for patient survival than for graft survival. 
This finding has not been pointed out earlier 
as all attention generally has been focused at 
graft survival. Many data from previous studies 
however support the correctness of this 
finding. Hill et al (1967) pointed out that the 
immediate postoperative mortality was di­
minished after some years of experiences while 
the late mortality, mainly due to infectious 
complications, seemed to remain unchanged. 
They also noticed that most of the patients who 
died late had functioning grafts. Moore and 
Hume (1969) stressed the fact that 80% of their 
transplanted patients who died had functioning 
grafts. When the importance of HL-A 
compatibility has been evaluated most authors 
have excluded patients who died with 
functioning grafts as "non-immunological" 
failures (Morris et al., 1970, Morris, 1971, 
Kissmeyer-Nielsen et al., 1971, Dausset & 
Hors, 1971, Batchelor et al., 1971, Arnos, 
1971). Also Terasaki and Mickey (1971) when 
discussing the problems of clinical evaluation 
of transplantation held the opinion that 
"non-immunological" deaths should be exc­
luded. They regarded e.g. myocardial infarc­
tion as a "non-immunological" death but 
suicide as a complication to the transplantation 
procedure and thus necessary to include. The 
myocardial infarction might however very well 
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be d ue to an immune response mechanism in 
the recipient or to the immunosuppressive 
therapy, i.e. a real "immunological" death. A 
suicide, if performed long after graft failure and 
because of a hopeless dialysis situation might 
on the other hand be excluded as a 
"non-immunological" death. 
It has thus been known that many 
transplanted patients die with functioning 
grafts late after the transplantation. In this 
series of transplantations such "non-
immunological" deaths occurred almost exclu­
sively amo ng patients receiving HL-A incom­
patible grafts. Thus the findings in this stu dy 
made it evident that HL-A compatibility w as 
the most important single factor for graft 
survival because of the influence of HL-A 
incompatibility on the recipient. 
How could incompat ible HL-A antigens be 
fatal for the recipients and why was an 
incompatible antigen not always fatal? Three 
different mechanisms should be considered 
here: 
1) The foreign HL-A antigen or its split 
products might have a direct toxic effect. 
Different antigens might be more or less toxic. 
As the chemical structures and properties of 
the HL-A antigens are still poorly kno wn the 
possibility of a direct toxic effect of certain 
HL-A antigens cannot be dismissed. On the 
other hand n o finding in this series or in other 
investigations support the suspicion of certain 
direct toxic HL-A antigens. An incompatible 
HL-A antigen might however constitute or 
raise a potential toxic sub stance lethal for the 
recipient only when some other certain 
conditions exist in the recipient, i.e. the antigen 
might induce a kind of graft-versus-host 
reaction. 
2) The recipient's response to the introduced 
foreign HL-A antigen might induce a lethal 
disease. The immune defence might damage 
the leukocytes and thrombocytes of the 
recipients making them incapable of func­
tioning adequately, i.e. a kind of auto-immune 
disease. 
The idea of an incompatibility induced 
auto-immune disease must be considered. If 
the fatal courses were consequences of too 
"strong" or "broad" immune response of the 
recipient they should have occurred more often 
among patients receiving less immunosuppres­
sion. On the contrary all but one of the 
recipients who died with functioning graft 
received the higher, intended immunosuppres­
sive d ose. 
3) The introduction of a foreign HL-A antigen 
might change the basic conditions for the 
recipient's tolerance to the medical treatment. 
This raised the question if th e incompatibility 
influenced the effect of the immunosuppres­
sive therapy and must be discussed further. 
The patients who died with functioning 
grafts died fairly late after the transplantation 
due to infectious, thrombo-embolic or bleeding 
complications. This clinical c ourse is cha rac­
teristic for too hard immunosuppressed 
patients. Such patients, who die with function­
ing graf ts because of too strong immunosup­
pressive treatment are found in every reported 
transplantation series. As already mentioned 
these patients usually h ave been excluded as 
"non-immunological" failures. In this series of 
transplantations the immunosuppressive 
therapy was well standardized and all patients 
received the same treatment. The only existing 
divergency was a lowerazathioprine dose given 
to 23 recipients who did not tolerate the 
intended dose because of bone-marrow depres­
sion. A lower azathioprine dose, although it 
was caused by a bone-marrow depression, 
rather seemed to protect the recipient from a 
fatal course. All patients but one, who died with 
functioning graft, received the higher, intended 
azathioprine dose. Of the patients who 
received the intended azathioprine dose no 
recipient with HL-A compatible graft died 
while 10 of 20 recipients of proved HL-A 
incompatible grafts died with functioning 
grafts. 
One possible explanation for this will be 
discussed. The introduction of a new incompat­
ible HL-A antigen into an individual stimulates 
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by definition a large proportion of the 
leukocyte population, larger than other an­
tigens outside the HL-A system. The metabo­
lites of azathiopri ne are antimetabolites which 
at the enzyme level interferes with the purine 
metabolism of cells. They have mainly a toxic 
effect upon cell division (Brent & Medawar, 
1966). The total effect of the azathioprine 
depends not only on the concentration of its 
active metabolites (Nathan et al., 1961, 
Tinberger, 1968, Hitchings & Elion, 1969) but 
also on the number of dividing, i.e. stimulated 
cells. HL-A compatible grafts stimulate a 
certain portion of the leukocyte population. 
The division of the stimulated cells is 
counteracted by the azathioprine, more 
effectively the higher the azathioprine concent­
ration. HL-A incompatible grafts stimulate the 
same proportion of the leukocyte population 
but moreover a much broader, "anti-HL-A-
population" of leukocytes. The higher the 
azathioprine concentration is the better is the 
immunosuppressive effect but also the better is 
the suppression of the "anti-HL-A-
population". This broader "not-only-graft-
specific" immunosuppression might be de­
leterious for the patient if another cross-
reacting antigen e.g. a bacterial or viral one, is 
introduced later. The portion of leukocytes 
stimulated by a second antigen might be a 
portion already stimulated by the foreign HL-A 
antigen and therefore damaged by the 
prolonged azathioprine therapy. This could 
explain the high incidence of deaths from 
infectious complications among recipients of 
HL-A incompatible g rafts. 
The divergent opinions of the correlations 
between HL-A compatibility grade and graft 
survival might then be explained by the 
different immunosuppressive treatment used in 
different transplantation centres. The deleteri­
ous HL-A-incompatibility-induced effect of 
azathioprine was only found when the higher 
dose was given. The immunosuppressive 
regimen is rarely descr ibed when the effect of 
HL-A compatibility is e valuated. It is known 
however that many transplantation centres are 
using lower azathioprine doses than in this 
series. Moreover antilymphocyte globulin was 
introduced as a new immunosuppressive agent 
almost simultaneously with the introduction of 
tissue-typing and was used routinely in many 
major transplantation centres. The addition of 
a new immunosuppressive drug often implied a 
reduction of other immunosuppressive drugs. 
Starzl et al (1968) e.g. decreased the mean daily 
azathioprine dose from 3.0 mg/kg to 1.9 mg/kg. 
Another immunosuppressive regimen might 
thus conceal the disadvantages of HL-A 
incompatibility by t he simultaneous reduction 
of the az athioprine dose. 
How then did the compatibility grade 
influence the g raft survival in cases in which 
the recipient did not die despite this azathiop­
rine sensitization? It is a well-known fact, often 
pointed out in the literature, that HL-A 
compatible grafts sometimes are rejected and 
HL-A incompatible grafts sometimes well 
accepted. In this series of transplantations 
irreversible rejections occurred with almost the 
same frequency in compatible and incompati­
ble grafts (Table XVII and Table XVIII). In fact 
the size of the given azathioprine dose was 
more important for graft survival than the 
HL-A compatibility grade (Table XXVII and 
Table XXVIII). Furthermore, irreversible 
rejections did occur in HL-A compatible grafts 
even when the higher azathioprine dose was 
given and HL-A incompatible grafts were 
accepted even when the lower azathioprine 
dose was given. 
The data obtained from this study indicate 
that HL-A compatibility was of minor or no 
importance for graft survival in the im-
munosuppressed recipients of primary nec-
rokidney grafts. HL-A compatibility was 
however of great importance for the recipients' 
ability to survive an immunosuppressively 
effective intended azathioprine treatment. 
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Chapter 8 
CONCLUSIONS 
1. In 64 consecutive primary necrokidney 
transplantations compatibility in t he HL-A 
system was found to be the most important 
single factor for overall graft survival during 
the first postoperative year. 
2. This better graft survival was not due to a 
lower frequency of irreversible rejections 
but to a superior patient survival. 
3. The degree of HL-A compatibility did not 
influence the survival of grafts in surviving 
patients. 
4. The most important single factor for patient 
survival was HL-A compatibility between 
donor and recipient. 
5. Patients transplanted with HL-A incompat­
ible grafts who died had most often 
functioning grafts at the time of death. They 
had received an intended mean daily 
azathioprine dose during the first postopera­
tive month of 2.9 mg/kg. 
6. Patients transplanted with HL-A incompati­
ble grafts and receiving a lower azathioprine 
dose survived. 
7. Patients transplanted with HL-A compatible 
grafts survived independent of the size of 
the azathioprine dose given. 
8. HL-A incompatibility was suggested to 
increase the risk for lethal toxic effects of 
azathioprine in the recipient. 
Compatibility in the HL-A system between 
donor and recipient was of minor importance 
for graft survival during the first year after 
primary necrokidney transplantation. It was 
however of great importance for the recipients ' 
ability to survive an immunosuppressively 
more effective azathioprine therapy. 
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